

Review

Not peer-reviewed version

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

[Kristian Alissa Choate](#) , [Evan P.S. Pratt](#) , [Matthew James Jennings](#) , [Robert James Winn](#) , [Paul Barrie Mann](#) *

Posted Date: 7 October 2024

doi: 10.20944/preprints202410.0393.v1

Keywords: Isocitrate Dehydrogenase; IDH1; IDH2; D-2-Hydroxyglutarate; D-2-HG; Epigenetics; Glioma



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

Kristian A. Choate^{1,2}, Evan P.S. Pratt^{1,3}, Matthew J. Jennings^{1,4}, Robert J. Winn^{1,5}
and Paul B. Mann^{1,4,*}

¹ Upper Michigan Brain Tumor Center, Northern Michigan University, Marquette, MI, 49855, USA

² Present address: Molecular & Cellular Biology Program, University of Washington, Seattle, WA, 98195, USA

³ Department of Chemistry, Northern Michigan University, Marquette, MI, 49855, USA

⁴ School of Clinical Sciences, Northern Michigan University, Marquette, MI, 49855, USA

⁵ Department of Biology, Northern Michigan University, Marquette, MI, 49855, USA

* Correspondence: pmann@nmu.edu

Simple Summary: In this review, we discuss the role of isocitrate dehydrogenase in a normal biological context and its subsequent role in oncogenesis when certain mutations are acquired. In particular, we focus on the many downstream effects of the oncometabolite D-2-Hydroxyglutarate, the byproduct of mutant isocitrate dehydrogenase. D-2-Hydroxyglutarate interferes with essential biological pathways that result in significant alterations to epigenetics, metabolism, RNA transcript stability, and DNA damage repair. Additionally, we review the diagnostic methods available for detecting isocitrate dehydrogenase mutations and/or D-2-Hydroxyglutarate. The clinical implications, including the classification of isocitrate dehydrogenase mutants in glioma and pharmaceutical inhibitors are also discussed.

Abstract: In 2021, the World Health Organization classified isocitrate dehydrogenase (*IDH*) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an *IDH* mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. *IDH* enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of *IDH* mutations in gliomas as well as current diagnostic techniques.

Keywords: isocitrate dehydrogenase; *IDH1*; *IDH2*; D-2-hydroxyglutarate; D-2-HG; epigenetics; glioma

Introduction

Gliomas are brain tumors associated with high mortality and life altering symptoms including seizures, cognitive/motor deficits, dysphagia, and aphasia [1]. Current treatment methods for glioma include surgical resection, radiation therapy, and chemotherapy with the use of temozolomide (TMZ). Despite these approaches, the long-term survival of patients remains poor. Approximately 30% of primary brain tumors are gliomas, which are believed to arise from neuroglial stem or progenitor cells [2]. Gliomas may be categorized as astrocytomas, oligodendrogliomas, oligo-astrocytoma, or ependymomas depending upon the cell type(s) from which they originate (Figure 1). When classifying these tumors, World Health Organization Central Nervous System 5 (WHO CNS5) grades ranging from I to IV are traditionally used, with grade I tumors being the least malignant [3]. To determine tumor grade, characteristics such as invasiveness, rate of growth, and degree of necrosis within the tumor are utilized. Gliomas may be diffuse in nature, which causes difficulty in both visualization via magnetic resonance imaging (MRI) and determination of margins during surgery, further complicating the identification and removal of malignant tissue.




Figure 1. Examples of neuroglial cells and glioma types resulting from malignant transformation. Glial cells support neuronal processes and maintain the surrounding environment. This figure was created with biorender.com.

Molecular analysis of the tumor allows for further classification of gliomas into subgroups. Classification of tumors provides valuable insight toward prognosis, and in some cases, the possibility of treatment with targeted therapies. Molecular classification may be accomplished with techniques including DNA/RNA sequencing, PCR, and DNA methylome profiling [4-6]. Various biomarkers have been established through the molecular classification of tumors, an example of which is isocitrate dehydrogenase (*IDH*). *IDH* enzymes play essential roles in metabolic processes such as the citric acid cycle, lipogenesis, glutamine metabolism, and redox regulation [7]. Oncogenic mutations to *IDH1* were identified in 2008 following an integrated genomic analysis of glioblastoma multiforme (GBM) [8], and have since been targeted with pharmaceutical inhibitors [9, 10]. The prognosis and treatment for *IDH* mutant gliomas differs from their *IDH* wildtype counterparts significantly, such that screening for them has become an important standard of care. Mutations to *IDH* have been documented in various types of cancer [11-13] but are more prevalent in glioma and acute myeloid leukemia (AML) [14, 15]. In general, *IDH* mutations are associated with less aggressive cancer, as they render cells more vulnerable to death [16] and demonstrate conservative levels of migration, angiogenesis, and invasion [17]. In this review, we describe the molecular, cellular, and clinical consequences of *IDH* mutations in glioma as well as the current diagnostic methods and treatments.

Normal Function of *IDH* & the Cancer-Associated Accumulation of D-2-HG

IDH1/2 are the most frequently mutated cancer-associated metabolic genes. *IDH* exists in three isoforms: *IDH1*, *IDH2*, and *IDH3*. *IDH1* and *IDH2* enzymes function as homodimers and share approximately 70% sequence homology [18]. Conversely, *IDH3* is a more distantly related heterotetrameric protein that is not known to be associated with the development of cancer [19]. *IDH1* is expressed in the cytosol and peroxisomes and produces NADPH for fatty acid biosynthesis, with oncogenic mutations commonly associated with glioma. Alternatively, *IDH2* localizes within the mitochondrial matrix, with mutations often driving AML, or less commonly, glioma [20]. *IDH1* and *IDH2* mutations are mutually exclusive, with rare exceptions [21], due to a common biochemical mechanism [22] that drives similar downstream effects. Ordinarily, *IDH1/2* catalyze the conversion of isocitrate into α -ketoglutarate (α KG) while reducing NADP⁺ to NADPH as a byproduct. Missense mutations yield amino acid changes at positions R132 in *IDH1* and R140 or R172 in *IDH2*. These mutations result in the replacement of conserved arginine residues in the catalytic site with an alternative amino acid. The consequence of these mutations is an altered protein with neomorphic activity- the conversion of α KG to D-2-Hydroxyglutarate (D-2-HG) [14, 23] (Figure 2). D-2-HG is an oncometabolite that accumulates in primary *IDH* mutant tumors at concentrations ranging from 1 to 30 mM [14, 23]. D-2-HG causes a plethora of downstream effects that mediate the development of cancer, as detailed below.




Figure 2. The difference in roles between wildtype and mutant IDH within the citric acid cycle. Wildtype IDH catalyzes the conversion of isocitrate to α KG. Mutations to conserved residues within the catalytic site of IDH elicit a gain-of-function that results in the aberrant conversion of α KG to D-2-HG. This figure was created with biorender.com.

Epigenetic Alterations

Epigenetic alterations are a hallmark of *IDH* mutant-mediated oncogenesis and are largely driven by the production of D-2-HG. Due to its structural similarity to α KG and accumulation within *IDH* mutant cells, D-2-HG competitively inhibits various α KG-dependent dioxygenases. These dioxygenases include the Jumonji-C (JmjC) family of histone lysine demethylases (KDMs), ten-eleven translocation (TET) DNA cytosine-oxidizing enzymes, AlkB homologs (ABH), and prolyl hydroxylases (PHD) [24] (Figure 3). α KG-dependent dioxygenases play critical roles in epigenetics [24], biosynthesis [25], post-translational modifications [26], and hypoxic response [27]. The collective antagonization of demethylases by D-2-HG leads to instability of RNA transcripts and characteristic patterns of hypermethylation of DNA and histone proteins [28]. Due to these epigenetic modifications, mutant *IDH* is highly associated with the Glioma CpG island methylator phenotype (G-CIMP) [29], a locus-specific pattern of DNA hypermethylation at CpG-rich promoter regions.




Figure 3. D-2-HG competitively inhibits various α KG-dependent dioxygenases. From left to right: YTHDC1 with N⁶-Methyladenosine (m⁶A), PHD2, TET2 in complex with DNA, the Jumonji domain of human Jumonji domain containing 1C protein. Crystal structures were sourced from Protein Data Bank (PDB); this figure was created using Biorender.com.

JmjC-KDMs

JmjC-KDMs are enzymes that regulate gene expression through demethylation and chromatin scaffolding functions [30]. The JmjC protein family contains >30 members [31], several of which may actively contribute to the development of cancers including glioma [32], acute myeloid leukemia [33], and lung cancer [31] when dysregulated. Numerous silenced, mutated, or deleted JmjC-KDM genes have been identified in cancer [34] and appear to act as either a driver or suppressor of gene expression, depending upon cellular context. Since JmjC-KDMs aid in the control of genome-wide expression patterns, aberrant protein function may result in significant changes to the transcriptomic profile of the cell [35]. Potential targets of dysregulated JmjC-KDMs include pro-inflammatory pathways such as signal transducer and activator of transcription (STAT)-dependent response or proliferation associated pathways such as mitogen-activated protein kinase (MAPK) [31].

In some cases, D-2-HG mediated inhibition of JmjC-KDMs results in downstream effects which function in a manner similar to knockout models. This phenomenon has been demonstrated by several members of the JmjC-KDM5 family of H3K4 histone lysine demethylases (KDM5A, KDM5C, and KDM5D). The inhibition of these JmjC-KDM5 enzymes occurs at physiologically relevant concentrations of D-2-HG (less than 1 mM) and is thought to contribute to *IDH* mutant-mediated transformation [36]. Of all potential α KG analogs (for example, fumarate, L-2-HG, succinate), D-2-HG is the most potent inhibitor of KDM4A/B and KDM6A with IC₅₀ values <200 μ M. Collectively, KDMs inhibited by D-2-HG contribute to the regulation of diverse cellular processes to include differentiation [37], growth and development [37, 38], adipogenesis [39], adhesion, and proliferation [33]. The competitive inhibition of several JmjC-KDMs by D-2-HG has been shown to increase dimethylation of H3K79, H3K27, and H3K9 as well as mono and trimethylation of H3K4 [40]. In combination with high levels of acetylation, H3K79 and H3K4 methylation are associated with active chromatin, with H3K79 found within the coding regions of genes and H3K4 often enriched at enhancers and promoters of actively transcribed genes. Conversely, H3K27 and H3K9 are associated

with inactive chromatin [41]; Thus, the pleiotropic effects of D-2-HG accumulation impacts a variety of different biochemical pathways resulting in oncogenesis.

Although the epigenetic changes mediated by JmJc-KDMs in *IDH* mutant cancers are profound, they are also readily reversible by the addition of α KG. 300 μ M α KG has been shown to negate the inhibition of KDM7A caused by up to 50 mM D-2-HG [40]. This reversibility demonstrates the relatively weak antagonism of JmJc-KDMs by D-2-HG despite occupying the same active site in the catalytic core. Regardless, *IDH1*-R132H mutations have shown a near 60% reduction of α KG and >20-fold increase in D-2-HG [40], suggesting that this competitive inhibition is due to metabolite quantity rather than changes to enzyme kinetics. Despite the inhibition of several JmJc-KDMs by D-2-HG, it is important to note that α KG-dependent dioxygenases vary greatly in their susceptibility to inhibition by D-2-HG, with some not significantly affected by relevant concentrations [34], such as KDM5B (IC₅₀ 3.6 mM) [42]. Recently, pharmaceutical inhibitors have been screened for their therapeutic potential toward inhibiting relevant JmJc-KDMs *IDH* mutant cancers, which we address later in this review.

Histone Deacetylases

Histone deacetylases (HDACs) possess chromatin remodeling activity and contribute to silencing genes in an epigenetic manner. HDACs hydrolyze acetate from lysine on histone tails [43], strengthening the interaction between histone proteins and DNA. HDACs are recruited to methylated DNA through their association with methyl-CpG binding proteins [44]. As hypermethylation is abundant in *IDH* mutant cancers, it is thought that HDACs play a role in transcriptomic alterations by compounding the effects of methylation to further condense chromatin near CpG islands. Expression profiles of *IDH* mutant glioma have demonstrated the upregulation of genes promoting HDAC function or related pathways in comparison to their *IDH* wildtype counterparts, including three of the six HDAC genes that are expressed in gliomas [45]. Additional studies have shown that overexpression of the *IDH* mutant enzyme results in histone hypoacetylation [46], further supporting the notion that HDACs play a role in *IDH* mutant oncogenesis. Several groups have presented HDAC inhibitors as a potential therapeutic for *IDH* mutant glioma, which we discuss later in this review.

TET Enzymes

TET enzymes are involved in various biological processes to include post-transcriptional regulation [47] and are essential for immune cell development [48] and embryogenesis [49]. TET enzymes generate oxidized derivatives of 5-methylcytosine (5mC) in a Fe(II)/ α KG-dependent manner. In these reactions, 5mC is sequentially oxidized to 5-hydroxymethylcytosine, 5-formylcytosine, then 5-carboxylcytosine. This oxidation typically occurs at CpG dinucleotide sites, where thymine DNA glycosylase excises 5-formylcytosine and 5-carboxylcytosine then base excision repair is utilized to yield unmethylated cytosine [47, 50]. Rather than being inert intermediates, the oxidation products of 5mC play unique and distinct biological roles and may also actively contribute to cancer in some cases [51]. For example, Johnson et al. observed the enrichment of 5-hydroxymethylcytosine in GBM at disease-specific enhancer elements to unexpectedly elicit open chromatin and increased gene expression [52]. To our knowledge, no data are currently available that explore the relationship between *IDH* mutant cancers and 5mC oxidation products.

The dysregulation of TET enzymes contributes to development of the G-CIMP through an increase in methylation [53] and subsequently alters the transcriptomic profile of *IDH* mutant cancers. Similar to JmJc-KDMs, TET enzymes are often mutated in various types of cancer such as AML and myelodysplastic/myeloproliferative neoplasms [54, 55]. TET and *IDH* driver mutations are mutually exclusive [56], suggesting that the inhibition of TET enzymes contributes significantly to mutant *IDH* mediated oncogenesis [46]. While TET or *IDH* mutations routinely occur in leukemia [47, 57], TET mediated oncogenesis is not typically thought to contribute to the development of glioma. TET enzymes are susceptible to competitive inhibition by the accumulation of D-2-HG, fumarate or succinate that result from oncogenic mutations to *IDH*, fumarase hydratase or succinate

dehydrogenase, respectively [58]; however, L-2-HG, a naturally occurring enantiomer of D-2-HG that is upregulated under hypoxic conditions [59], does not appear to interfere with TET activity intracellularly. To this end, the use of cell-permeable L-2-HG to quantify TET enzymatic inhibition demonstrates that treatment with up to 3 mM of L-2-HG elicits little to no inhibition of TET2 or TET3 *in situ* [60].

Despite the oncogenic consequences of TET dysregulation, not all members of the TET family are prone to inhibition by clinically relevant concentrations of D-2-HG. For example, TET2 has demonstrated inhibition at low levels of D-2-HG *in vitro* ($IC_{50} = \sim 15 \mu M$) while TET1 ($IC_{50} = \sim 800 \mu M$) and TET3 ($IC_{50} = \sim 100 \mu M$) are less susceptible. Although TET2 is the most prone to competitive inhibition by D-2-HG, TET1 and TET3 are highly expressed in specific areas of the brain including the cerebellum and cerebral cortex, respectively, while the expression of TET2 in the brain is somewhat modest [47]. Another potential variable regarding the inhibition of TET enzymes in *IDH* mutant cancers is the availability of ascorbic acid (vitamin C). Ascorbic acid modulates TET enzymes via a direct interaction with their catalytic domain [61] and reduces Fe(III) to Fe(II), an essential cofactor of TET. Indeed, co-administration of pharmaceutical mutant *IDH* inhibitors and ascorbic acid has been shown to restore TET activity in *IDH1*-R132H colorectal cancer cell lines [62]. Additional studies have demonstrated that supplementation with an oxidatively stable form of vitamin C (Ascorbate-2-phosphate) can restore 2-HG induced epigenetic remodeling [63]. Because *IDH* mutations alter $NADP^+/NADPH$ ratios and NADPH is a cofactor in recycling ascorbate, it is possible that vitamin C availability and D-2-HG accumulation have a combinatorial effect towards the dampened TET activity witnessed in *IDH* mutant cancers. To this end, an *in vivo* knock in model of *IDH1*-R132H has demonstrated altered $NADP^+/NADPH$ ratios with a coinciding decrease in ascorbate within the brain [64].

Prolyl Hydroxylases & Hypoxic Response

In addition to epigenetic modifications, αKG -dependent dioxygenases may also play key roles facilitating decisions regarding cell fate such as normal differentiation [65] and regulation of hypoxia inducible factor 1 (*HIF-1 α*) [66]. Due to the rapid proliferation of tumors, hypoxia is frequently observed in the microenvironment as existing blood supplies are outgrown. *HIF-1 α* is a transcription factor that is upregulated in response to low oxygen, including under inflammatory conditions [67], to induce the expression of various genes essential for cell survival and adaptation to a hypoxic environment [68]. PHDs utilize αKG as a substrate to selectively hydroxylate targets and are susceptible to dysregulation by the accumulation of D-2-HG [69]. Under ordinary conditions, *HIF-1 α* is constitutively expressed and rapidly degraded by PHDs. Low levels of oxygen inhibit PHDs, resulting in elevated expression of *HIF-1 α* and subsequently the upregulation of hypoxia associated genes.

Egln prolyl-4-hydroxylases ordinarily mark *HIF-1 α* for polyubiquitylation and proteasomal degradation [70]; however, literature disagrees on whether D-2-HG stimulates or inhibits these PHDs. Some studies suggest that D-2-HG acts as a co-substrate to PHDs resulting in the destabilization of *HIF-1 α* and reduced expression of associated genes [71]. The knockdown of PHDs in *IDH* mutant astrocytes was also shown to result in a marked reduction in proliferation, suggesting a potential role for *HIF-1 α* as a tumor suppressor [69]. As ascorbic acid availability is lowered by the altered $NADP^+/NADPH$ ratios in *IDH* mutant cancers [64], it should also be noted that ascorbate encourages hydroxylase activity to suppress the transcriptional response of *HIF-1 α* [72, 73]. To this end, a decrease in ascorbate availability could also contribute to a decrease in the expression of hypoxia associated pathways; however, this relationship has never been explored.

Contrary to findings that *HIF-1 α* is downregulated in *IDH* mutant cancers, many others have shown that *HIF-1 α* is upregulated in *IDH* mutant cells, cells treated with exogenous 2-HG, *IDH* mutant tumors, and brains of mouse embryos expressing *IDH1*-R132H [40, 64, 74, 75]. The notion of an increase in *HIF-1 α* resulting from metabolically driven oncogenesis such as *IDH* is supported by cancers driven by a similar mechanism. Oncogenic mutations to fumarate hydratase or succinate dehydrogenase result in the accumulation of fumarate or succinate, respectively, which act in a

similar manner to D-2-HG by competitively inhibiting α KG-dependent dioxygenases. In these instances, fumarate or succinate have been shown to inhibit α KG-dependent PHDs that target HIF-1 α for degradation [76, 77], resulting in its subsequent accumulation.

RNA Transcript Stability

The methylation of adenosine at the nitrogen-6 positions of RNA (N⁶-Methyladenosine, m⁶A) serves as an essential posttranslational regulatory mark of mRNAs and noncoding RNAs. In addition to playing a role in most RNA-related processes such as splicing and nuclear export, m⁶A is also associated with biological processes including transcriptional regulation, signal transduction, DNA damage response [78], and cancer [79]. m⁶A is a frequent internal modification of mRNA which recruits m⁶A binding proteins such as YTHDF1/2/3, YTHDC2, or IGF2BP1/2/3 to regulate stability and/or translation efficiency [79]. m⁶A modifications are ordinarily facilitated by methyltransferases and removed by demethylases such as fat mass and obesity-associated protein (FTO) or ALKBH5 which are Fe(II)/ α KG-dependent dioxygenases [80].

IDH wildtype cells treated with D-2-HG or *IDH* mutant cells producing D-2-HG exhibit an increase in m⁶A levels that can be reversed through treatment with *IDH* mutant pharmaceutical inhibitors such as Vorasidenib [81]. Since *IDH* mutant pharmaceutical inhibitors are known to deplete D-2-HG, these results support the role of the oncometabolite toward m⁶A accumulation. Moreover, D-2-HG has demonstrated a dose-dependent inhibition of FTO [81] that causes an increase in m⁶A levels [82-84]. The knockdown of endogenous FTO recapitulates the impacts of D-2-HG on cell viability, increases m⁶A levels [83], and promotes apoptosis and cell-cycle arrest at the G₀/G₁ phase [84]. Similarly, pharmacologic inhibition of FTO using FB23-2 or meclofenamic acid result in decreased proliferation and increased apoptosis. In addition to FTO, D-2-HG also inhibits ALKBH5; however, D-2-HG has a weaker binding affinity for ALKBH5 than FTO and the knockdown of ALKBH5 alone does not recapitulate the increase in m⁶A seen in FTO knockout lines or *IDH* mutant cells [81]. These results suggest that FTO inhibition is the primary mechanism of m⁶A accumulation in *IDH* mutant cells.

Increased levels of m⁶A result in lower stability of mRNA transcripts with a notable target of D-2-HG mediated transcript decay being the oncogene *MYC* [83]. Interestingly, ectopically expressing *MYC* rescues D-2-HG mediated growth inhibition [84]. Further studies have shown that m⁶A-mediated downregulation of activating transcription factor 5 (*ATF5*) mRNA may also play an important role in regulating proliferation and apoptosis in *IDH* mutant glioma [81]. In addition to impacting proliferation, m⁶A levels modify the metabolic profile of cells, with the largest impacts being the downregulation of phosphofructokinase platelet (PFKP) and lactate dehydrogenase B (LDHB) [84].

While TET enzymes are largely known for facilitating the active demethylation of DNA, recent studies have also demonstrated that TET2 contains an RNA-binding domain [85] and can oxidize 5-methylcytosine RNA into 5-hydroxymethylcytosine. Since 5-hydroxymethylcytosine is associated with active translation of mRNA [86], aberrant post-translational mRNA modifications by TET2 reduce transcript stability which may increase susceptibility to certain diseases [87]. With these recent findings, further studies are necessary to determine the specific impact of TET-mediated mRNA alterations in *IDH* mutant glioma.

Patterns of Transcription

The many epigenetic alterations within the *IDH* mutant genome have various downstream implications for the transcriptome. Tran et al., assessed RNA sequencing (RNAseq) and microarray data for 1032 gliomas from the cancer genome atlas and 395 gliomas from REMBRANDT and found four distinct transcriptomic profile groups. Interestingly, *IDH* mutant gliomas with codeletions were grouped with oligodendrogliomas with high tumor purity. Transcriptomic data for this group was enriched for neurotransmission, G-protein coupled receptor signaling, and insulin secretion pathways. Alternatively, *IDH* mutant gliomas without codeletions generally corresponded with astrocytoma and transcriptomic data enriched for immune, cell cycle, NOTCH signaling,

transcription, and translation [88]. In a similar study, Cheng et al., utilized RNAseq data to establish a six-gene risk signature for *IDH* mutant low-grade glioma to assist in determining risk and prognosis. The six genes found to be highly significant for prognosis in *IDH* mutant patients included: cell division cycle (CDC) 20, Wiskott-Aldrich syndrome protein family (WASF)3, deleted in breast cancer (DBC)1, engrailed (EN)2, vimentin (VIM), and carboxypeptidase (CPE). Higher expression of CDC20, EN2, and VIM was found to be associated with risk while WASF3, DBC1, and CPE were considered protective genes with higher expression levels associated with better prognosis [89]. Another study focusing on transcriptomic profiles compared *IDH* mutant gliomas and *IDH* mutant AML, melanoma, and cholangiocarcinoma. Interestingly, these profiles showed pro-malignant genes unique to *IDH* mutant gliomas while genes associated with differentiation and immune response were suppressed in all *IDH* mutant cancers. Moreover, *IDH* mutant gliomas demonstrated a higher degree of genes that were both hypermethylated and differentially expressed in comparison to other types of *IDH* mutant cancers. Unruh et al. also noted variances in differential gene expression between *IDH* mutant oligodendrogliomas and astrocytoma, with oligodendrogliomas downregulating genes linked to angiogenesis, cell proliferation, and integrin binding [90]. Additionally, analysis of transcriptomic profiles of *IDH* mutant glioma patients revealed the decreased expression of HIF-1 α targets as well as the inhibition of angiogenesis and vasculogenesis. Specifically, the expression of EGLN1 and EGLN3 PHDs, which serve to degrade HIF-1 α was upregulated while pro-angiogenic targets such as vascular endothelial growth factor A, angiopoietin-2 and platelet-derived growth factor A was decreased [27].

Metabolic Reprogramming in *IDH* Mutant Glioma

Comparison of Wildtype and Mutant IDH Reactions

Wildtype *IDH* catalyzes the oxidative decarboxylation of isocitrate into α KG and CO₂. This reaction occurs concomitantly with the reduction of NADP⁺ into NADPH, with the exception of *IDH3*, which generates NADH within the citric acid cycle [91]. Under certain circumstances (e.g. hypoxia), *IDH* can catalyze the reverse reaction – the reductive carboxylation of α KG into isocitrate, generating NADP⁺ as a byproduct [92]. Isocitrate is subsequently isomerized into citrate, which is broken down by ATP citrate lyase into acetyl-CoA. Acetyl-CoA can be used for fatty acid biosynthesis under these conditions [93].

Hotspot mutations within the active site of *IDH1* (R132X) and *IDH2* (R140X or R172X) render the enzymes capable of catalyzing a new reaction - the conversion of α KG into D-2-HG. This is in contrast to the reverse reaction catalyzed by wildtype *IDH1* that produces isocitrate. Mutant *IDH*-driven D-2-HG accumulation is coupled with the oxidation of NADPH into NADP⁺. Unlike wildtype *IDH*, mutant *IDH* consumes both α KG and NADPH, which is likely to impact cellular metabolism and redox homeostasis, respectively.

D-2-HG is classified as an oncometabolite and is almost exclusively produced by *IDH* mutant cells [14], although there is evidence that other enzymes, including phosphoglycerate dehydrogenase, produce minute amounts of the oncometabolite in cells [94]. Mutant *IDH*-mediated D-2-HG accumulation is a molecular hallmark of astrocytoma and oligodendroglioma [95]. Importantly, D-2-HG production drives metabolic rewiring in these types of cancer, including but not limited to dysregulation of glucose metabolism, the citric acid cycle, amino acid metabolism, lipid and cholesterol metabolism and redox homeostasis.

Mutant IDH Cells Do Not Perform Aerobic Glycolysis

Perhaps the most well-known example of metabolic reprogramming is the overconsumption of glucose by cancer cells to meet growing energy demands [96]. Cancer cells are also known to produce and secrete copious amounts of lactate as a result of pyruvate metabolism, despite the presence of O₂. This phenomenon is better known as aerobic glycolysis or the Warburg effect. Interestingly, *IDH* mutant glioma do not appear to follow this framework. Glycolytic flux is reduced in *IDH1* mutant glioma tumors compared with *IDH1* wildtype tumors as a result of dampened expression of the rate-

limiting glycolytic enzymes hexokinase and pyruvate kinase [97]. In agreement with this, lower quantities of glycolytic intermediates, including fructose 1,6-bisphosphate, 3-phosphoglycerate and phosphoenolpyruvate, have been observed in *IDH1* mutant glioma tissue [95].

IDH mutant glioma tissue and brain tumor stem cells derived from *IDH1* mutant glioma tissue show reduced expression of lactate dehydrogenase A (LDHA), the enzyme responsible for converting pyruvate into lactate [98]. Silenced LDHA expression is associated with hypermethylation of the *LDHA* promoter, which is likely to be a direct result of inhibition of α KG-dependent DNA demethylases by D-2-HG. This relationship, along with other *IDH*-mutant specific metabolic and epigenetic aberrations, is summarized in Figure 4. This is accompanied by decreased expression of monocarboxylate transporters (MCT) 1 and 4, both of which are involved in the efflux of lactate from the cell. Overall, this suggests that *IDH1* mutant cells do not perform aerobic glycolysis. Indeed, lactate levels are undetectable in *IDH1* mutant neurospheres [99]. Interestingly, the enzyme LDHB, which is involved in converting lactate to pyruvate, and the lactate importer MCT2 are more abundant in *IDH1* mutant glioma tissue compared with wildtype samples [100]. This suggests that lactate may serve as an anaplerotic substrate for pyruvate accumulation.




Figure 4. The molecular impacts of IDH mutations discussed in this review. Metabolic rewiring and D-2-HG mediated inhibition of α KG-Fe(II)-dependent dioxygenase play important roles in the unique phenotype of IDH mutant cells. This figure was created with Biorender.

Citric Acid Cycle Rewiring in IDH Mutant Cells

The citric acid cycle is the cornerstone of cellular metabolism [101]. This pathway is directly involved in energy production and supplies metabolic intermediates for the generation of fatty acids, amino acids and nucleotides. Although IDH3 is the only IDH isozyme that directly participates in the citric acid cycle, both IDH1 and IDH2 help regulate levels of cellular α KG and control redox homeostasis. There is strong agreement among various studies that the citric acid cycle is rewired in IDH1 mutant gliomas. Elevated expression of citric acid cycle enzymes upstream of IDH, including citrate synthase and aconitase, has been reported [97]. In addition, there is decreased expression of enzymes downstream of IDH, including succinate dehydrogenase and fumarase. These findings are supported by studies showing that citric acid cycle intermediates downstream of IDH, including α KG, succinate and fumarate, are decreased [102, 103].

Anaplerotic reactions serve to replenish citric acid cycle intermediates, maintaining cycle flux [101]. Three common anaplerotic nutrients are glutamate (converted to α KG by glutamate dehydrogenase), glutamine (converted to glutamate by glutaminase) and pyruvate (converted to oxaloacetate by pyruvate carboxylase). As α KG is consumed by mutant IDH, the metabolism of both glutamate and glutamine would be expected to be particularly important. Indeed, both glutamate and glutamine levels are significantly decreased in U87MG cells expressing the IDH1-R132H mutant, compared with wildtype cells [104]. In partial agreement with this finding, patient-derived IDH1-R132H xenografts showed elevated expression of glutamate dehydrogenase and lower levels of glutamate in mouse brains, suggesting that glutamate metabolism is increased in IDH1 mutant tissue [97, 105, 106]. However, the authors found no significant difference in the expression of glutaminase or cellular glutamine levels. Somewhat surprisingly, another study found no differences in glutamate or glutamine levels between IDH1 wildtype and IDH1 mutant human glioma tumor samples [97]. Thus, it appears that glutamate versus glutamine usage by IDH mutant cells is context-dependent and requires further exploration.

It is worth noting that pyruvate carboxylase expression was elevated in immortalized human astrocytes expressing the IDH1-R132H mutant and in human glioma tissue [104]. This suggests that regardless of whether α KG is primarily derived from glutamate or glutamine, pyruvate carboxylase may take the driver's seat as the primary anaplerotic reaction in the citric acid cycle.

Mutant IDH Drives Changes In Amino Acid Metabolism

McBrayer et al. discovered that expression of IDH1-R132H in glioma cell lines elicits an upregulation in glutaminase expression [107]. Interestingly, the authors concluded that enhanced glutamine catabolism was being used to primarily support glutamate production, as opposed to α KG. Glutamate levels were decreased in the mutant cell line as a direct result of branched-chain aminotransferase 1 and 2 (BCAT1/2) inhibition by D-2-HG. As expected, the authors found that the mutant IDH1 cells had increased levels of the branched-chain amino acids (BCAA) valine, isoleucine and leucine. Two additional studies support the finding that BCAT1/2 expression and activity is decreased in IDH mutant tumors compared with wildtype tumors [97, 108]. However, Tonjes et al. suggested that reduced activity of BCAT1/2 could be attributed to lower levels of α KG due to mutant IDH activity.

In addition to lower levels of BCAAs, IDH1 mutant glioma tissue contains decreased concentrations of the amino acids glycine and serine [95]. Glycine and serine are integral to one-carbon metabolism, suggesting potential impairments in this metabolic network. In one-carbon metabolism, the interconversion of glycine and serine by the enzyme serine hydroxymethyltransferase is coupled with the folate cycle, the methionine cycle and nucleotide biosynthesis [109]. However, an in-depth analysis of these pathways in IDH mutant glioma is lacking.

Consumption of NADPH by the Mutant IDH Enzyme

NADPH is produced in the canonical reaction catalyzed by wildtype IDH, whereas mutant IDH consumes NADPH in the reaction that produces D-2-HG. As expected, U87MG glioma cells expressing the *IDH1*-R132H mutant and patient-derived xenografts from *IDH1* mutant GBM both showed lower cellular NADPH levels and a decreased [NADPH]/[NADP⁺] ratio [102, 103]. Fack et al. found that [NADH]/[NAD⁺] was not different between *IDH1* wildtype and mutant tumors; however, Biedermann et al. detected less NAD⁺ in the mutant U87MG cells, suggesting that NAD⁺ could be used to replenish cellular NADPH. As a potential explanation for how redox homeostasis can be restored in *IDH* mutant cells, Hollinshead et al. found that human anaplastic oligodendroglioma cells expressing the *IDH1*-R132H mutant had increased expression of the enzyme proline 5-carboxylase reductase 1 (PYCR1), which is involved in proline biosynthesis [110]. The authors found that not only did the *IDH1* mutant cell line accumulate proline as a result of increased PYCR1 activity but NADH consumption in this reaction was a means to uncouple the citric acid cycle from NADH usage in oxidative phosphorylation.

The oxidative pentose phosphate pathway is recognized as the major producer of cytosolic NADPH. NADPH is primarily used for fatty acid biosynthesis and to maintain the cellular pool of reduced glutathione for mitigating ROS. Unfortunately, the impact of reduced NADPH levels in *IDH* mutant glioma cells specifically is largely lacking. In line with studies performed in glioma cells, HCT116 colon cancer cells expressing the *IDH1*-R132H mutant consume significantly greater quantities of NADPH compared with wildtype cells [111]. This leads to an increase in the cellular demand for NADPH, amplifying flux through the NADPH-producing pentose phosphate pathway. Interestingly, both *IDH1*-R132H mutants and *IDH2*-R172K mutants are more susceptible to oxidative insults. Gelman et al. also found that the *IDH1* mutation created competition between the production of D-2-HG and the fatty acid palmitate in colon cancer cells. Fibrosarcoma cells expressing another *IDH1* mutant (R132C) consume NADPH at the same rate as *de novo* lipogenesis [112]. These cells have increased reliance on exogenous lipids for growth.

Dysregulation of Membrane Lipid Biosynthesis

The biosynthesis of fatty acids, membrane lipids and cholesterol is perturbed in *IDH1* mutant glioma. Three *IDH1* mutant glioma models, including human glioma xenografts in mice, cultured glioma cell lines and human glioma biopsies, showed a distinct phospholipid profile characterized by low levels of phosphoethanolamine and heightened levels of phosphatidylcholine [113]. In contrast, another study showed the phosphatidylcholine levels were decreased in U87MG cells expressing the *IDH1*-R132H mutation [114].

DNA Damage Repair

Various studies have demonstrated that cells with an *IDH* mutation have heightened sensitivity to DNA damaging agents. This increased sensitivity is partially mediated by the inhibition of ABH enzymes including ALKBH2 and ALKBH3. ALKBH2/3 remove alkyl adducts from nucleobases via oxidative dealkylation [115], and the inhibition of these enzymes by D-2-HG reduces the repair kinetics of *IDH* mutant cells resulting in the accretion of DNA damage. Since ABH proteins are α KG-Fe(II)-dependent dioxygenases, the accumulation of D-2-HG impedes normal function, resulting in a 73-88% inhibition of normal DNA repair activities [116]. Ratios of D-2-HG: α KG in patients have been observed at approximately 373:1, while D-2-HG concentrations are dependent upon the source, but in tissues can accumulate up to almost 2 mM [117]. For experiments gauging D-2-HG inhibition of DNA repair activities, Chen et al. utilized a 373:1 ratio of D-2-HG: α KG and concentrations of D-2-HG varying from 0-37 mM. Interestingly, like other dioxygenases that rely upon α KG, this inhibition is reversible if the *IDH* mutation (and consequently the production of D-2-HG) is lost [118]. The presence of excess α KG can also assist in reversing this inhibition [116].

In addition to ALKBH2/3, *IDH* mutant cells also demonstrate an impaired ataxia-telangiectasia-mutated (ATM) signaling pathway, which is an essential mediator of cellular response to double

stranded breaks (DSB) [119]. Upon the occurrence of a DSB, ATM is recruited to the damage site then initiates DNA damage repair (DDR) complexes by phosphorylating various targets including checkpoint kinases and p53 to begin the repair process [120]. Further investigation into the mechanism of the *IDH* mutant specific downregulation of ATM has demonstrated that the reduced expression of ATM is due to D-2-HG mediated histone methylation of H3-K9 by KDM4 [121]. The use of pharmaceutical inhibitor AGI-5198 with *IDH* mutant patient-derived cultured glioma cells has demonstrated the downregulation of essential epigenetic reader Zinc Finger MYND-Type Containing 8 (ZMYND8) [122]. ZMYND8 recognizes modifications such as acetylation and methylation, facilitates DNA repair in the presence of DSB, and may act as either a repressor or enhancer of transcription [123]. KDM5A-dependent H3K4me3 demethylation near DSB is required for the colocalization of ZMYND8 and subunits of the nucleosome remodeling (NuRD) and histone deacetylation complex including HDAC1/2 and chromodomain helicase DNA binding protein 3-5 (CHD3/4/5) [124]. Lending to the known sensitivity of *IDH* mutant cells to poly(ADP) ribose (PARP) inhibitors [125], it is also of note that ZMYND8/NuRD facilitated repair is dependent upon poly(ADP) ribose. To this end, treatment with PARP inhibitors has been shown to abolish ZMYND8 recruitment in cultured cells [124], and the knockdown of ZMYND8 in *IDH* mutant patient-derived cultured glioma cells resulted in increased sensitivity to radiotherapy as well as significant phosphorylation of ATM and γ H2AX activation in response to ionizing radiation [122].

Despite several known mechanisms for increased vulnerability to DNA damage, variable results exist concerning the response of *IDH* mutant cells to radiation-induced DNA damage. In some cases *IDH* mutant glioma cells have demonstrated a decreased sensitivity to radiation-induced DNA damage in comparison to *IDH* wildtype cells [126]. A potential theory for this unexpected finding posited by the authors is that *IDH* mutant cells must develop buffering mechanisms against high levels of ROS to survive, thus making them better equipped to survive ROS generated from radiation damage. Despite these findings, other groups have shown the opposite: that *IDH* mutations increase sensitivity to radiation due to delayed DNA repair [127, 128]. For example, when treated with TMZ, *IDH* mutant cells have an IC_{50} less than half that of *IDH* wildtype cells [119]. Since the mechanism of TMZ is to disrupt DNA structure via the addition of alkyl groups, this heightened sensitivity suggests weakened DDR response.

Conflicting results regarding the response of *IDH* mutant cells to DNA damage could potentially be explained by the genetic complexity found within the tumor environment that varies between patients and is often not accounted for with isogenic knockout models. To this end, several mutations that commonly co-occur with *IDH* mutations [specifically inactivating *TP53* [129] and alpha thalassemia/mental retardation syndrome X-linked gene (*ATRX*) [130]] have been shown to contribute to genomic stability, enhanced DNA repair, and resistance to genotoxic therapies [131]. Thus, although this relationship has not been extensively explored, it is possible that discrepancies in DDR data are due to co-occurring deletions or other complex genetic factors.

Immunological Impact of *IDH* Mutations in Glioma

The immunological implications of *IDH* mutations in glioma has recently been extensively covered [132].

Diagnostics

Efforts to identify and classify biomarkers have yielded valuable targets for diagnostics treatment, with *IDH* mutant cancers being a key example in glioma. Techniques that may elucidate the *IDH* mutational status prior to surgical resection remains urgent, as overall survival improves with a maximal surgical resection [133]. Still, CNS malignancies pose unique challenges, with the acquisition of tissue remaining at the forefront. While tissue-based assays remain valuable, many cannot function in a manner rapid enough to provide information capable of guiding the extent of surgical resection. However, strategies leveraging D-2-HG as a surrogate biomarker show great promise for facilitating early detection and monitoring of disease state. Additionally, MRI-based

techniques have been highly successful for the early detection of IDH mutant gliomas. Here, we discuss some of the molecular diagnostic techniques developed for the detection of IDH mutations.

Sequencing

The development of assays to successfully detect the *IDH* mutant genotype has been challenging, particularly due to the heterogeneity of gliomas [134-136] and heterozygosity of *IDH* mutations [137], which collectively lend to low copy number within a sample. Currently, the sequencing of DNA serves as one of the most comprehensive and relied upon methods for characterizing the molecular profile of tumors. Sequencing is particularly beneficial as it is adept at identifying a variety of genetic abnormalities including single nucleotide variants (SNV), indels, and structural variants. The detection of SNVs is particularly relevant for identifying *IDH* mutations, as traditional PCR or other amplification-based methods struggle to identify the single base changes needed to differentiate between the wildtype and mutant genotype. Furthermore, there is evidence that sequencing-based detection is a more reliable indication of *IDH* mutational status than IHC [138], which is currently considered a gold standard.

Next generation sequencing (NGS) and third generation sequencing platforms are advantageous as they are high throughput and can successfully identify both known and novel transcripts. However, without precursor targeted enrichment, NGS-based systems may struggle with accurately detecting low-level variants and have reported detection limits between 2-15% variant allele frequency (VAF). Using NGS, Vij et al., found the VAF of *IDH1*-R132H mutations to be 0.8%, a value significantly lower than other clinically relevant mutations in glioma such as *ATRX* [139]. While highly sensitive methods like real-time PCR (as low as 0.0002%) [140] are appealing alternatives for low abundance targets, they typically lack SNV discrimination and lack the high throughput of sequencing-based applications. On the contrary, sequencing-based applications can provide unbiased results for new or previously known SNVs. Additionally, targeted sequencing with user-defined primer sets to enrich specific genes or regions allow for the detection of VAF as low as 0.1-0.2% to be achieved [141]. When using sequencing for diagnostic applications in cancer, whole genome sequencing can be used; however, it often poses a significant time and cost burden. Thus, panels targeting known biomarkers are often employed dependent upon cancer type. Panels are beneficial for saving time and costs, but also allow for increased sequencing depth [142] and thus, more reliable results. For gliomas, these panels generally target key biomarkers such as *IDH1*, *TP53*, telomerase reverse transcriptase (*TERT*), and *ATRX* [143-147]. While methods using NGS techniques such as ion-torrent [144, 146-148] and Illumina [145, 149, 150] have been developed to detect *IDH* mutations, third generation techniques such as oxford nanopore technology (ONT) [151-153] have recently gained traction as well. These ONT platforms have demonstrated variant detection limits within the general range of those seen in NGS-based systems (3.3% and

DNA sequencing is most commonly used for diagnostic purposes; however, RNA sequencing (RNAseq) assays have also been developed to include *IDH* mutations [154]. RNAseq offers some advantages over DNA sequencing, such as the direct detection of rare splice variants, accurate measurements of gene expression, and detection of non-coding RNA species [155]. RNAseq also serves as a valuable approach toward transcriptome profiling and can provide single-cell resolution [156] and spatial information [157]. RNAseq has the potential to uncover cell-type specific treatment responses, better understand disease mechanisms, and provide quantitative transcriptome-wide data from tissue sections [157]. Using single-cell RNAseq (scRNAseq) of GBM samples, Couturier et al., generated a hierarchical map to uncover therapeutic targets of progenitor cancer stem cells [156]. Specific to *IDH* mutant glioma, scRNAseq has been utilized to explore the identity of progenitor cells for astrocytoma vs oligodendroglioma, as well as identify differences in their respective tumor microenvironments. For example, the data of Venteicher et al., suggest a common progenitor cell type for astrocytoma and oligodendroglioma IDH mutant glioma, [158]. While high cost will likely hinder the widespread implementation of RNAseq in a clinical setting in the immediate future, basic research with these techniques may yield valuable targets for novel therapeutics to improve overall survival.

Sequencing is commonly employed with DNA purified from fresh frozen tissues or formalin-fixed paraffin embedded tissues (FFPE) [143-149]. Additionally, sequencing for the detection of *IDH* mutations has been successfully performed on cell-free circulating DNA (cfDNA) derived from CSF [159]. Genetic characterization via liquid biopsies has been particularly challenging in gliomas, with low copy number attributed to the blood-brain barrier. Current data supports that the quantity of cfDNA increases with proximity to the tumor [160], with CSF yielding the highest quantity and fluids like blood [161] and urine proving to be more challenging sample types. To this end, amplification-based library preparation methods such as multiplex PCR can be helpful in enriching samples of interest prior to sequencing. Additionally, others have applied Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) based systems toward the targeted enrichment of regions of interest. An example of this is nanopore Cas9 Targeted Sequencing (nCATS), which selectively ligates sequencing adapters to CRISPR-Cas cut sites by dephosphorylating DNA ends before cleavage occurs, then preferentially ligating to the freshly cut/phosphorylated DNA ends at the cleavage site. nCATS has been utilized to simultaneously determine the *IDH* mutational status and Methyl Guanine Methyl Transferase (MGMT) methylation status in fresh glioma biopsies [162]. CRISPR-based detection of *IDH* mutations has also been utilized directly with CRISPR-Cas12a [163, 164]. CRISPR-Cas12a binds DS DNA with high specificity, which then induces non-specific (collateral) cleavage of single stranded DNA. Various groups have exploited the unique properties of Cas12a by including single stranded DNA probes that emit fluorescence when cleaved [165, 166]. Despite the broad applications of CRISPR-based diagnostics, evidence exists to indicate prevalent nonspecific cleavage of DS DNA by Cas12a [167], and some groups have even attempted to generate variants with more stringent recognition [168].

Epigenetic Detection

As the epigenetic effects of *IDH* mutations ultimately lead to G-CIMP [29], several groups have identified methylome profiling as an alternative method of diagnosis [169-173]. In an analysis of mixed tumor samples, a pairwise similarity heatmap yielded two major clusters- gliomas with and without *IDH* mutations [174], demonstrating that the characteristic nature of global methylation patterns can be used to differentiate between the *IDH* wildtype and *IDH* mutant genome. Epigenetics can also serve as an indication of changes to disease state, as the overall methylation level has been found to decrease during progression [171]. Another benefit to methylation profiling is that it can inclusively recognize oncogenic variants of *IDH1/2* and can be further subclassed into tumor type based on epigenetic marks (for example, astrocytoma or oligodendroglioma) [170, 175]. Methylation status has been interrogated using Nanopore sequencing [173, 176] and methylation profiling arrays [170-173] and can be performed using snap frozen or FFPE tissue. Nanopore sequencing for the determination of methylation status is particularly advantageous because it does not require a precursor bisulfite treatment, which is associated with DNA degradation [177] and is rapid enough to adapt for intraoperative use [176]. As discussed later, a more aggressive surgical resection for glioma patients with an *IDH* mutation is associated with greater survival benefit [178-180], making simple assays capable of performing intraoperatively valuable tools for clinicians seeking to use this information to guide the extent of resection.

Amplification-Based Detection

Amplification methods for the detection of *IDH* mutations are frequently adapted to discriminate between SNVs while retaining the sensitivity necessary for detecting relatively low copy number in a high background of non-target nucleic acids. PCR-based amplification is highly characterized, broadly available, and has long been considered a gold standard in clinical practice. The PCR-based detection of *IDH* mutations has been accomplished with several variations and/or adaptations, including digital droplet PCR (ddPCR) [181] qRT-PCR [182], and multiplex PCR coupled to a SNaPshot assay [183]. Another modification of PCR, Beads, Emulsion, Amplification, Magnetics (BEAMing) RT-PCR has also been adapted for the detection of *IDH* mutations [184]. BEAMing PCR is an adaptation of emulsion PCR that meets the need for detection of low frequency alleles in a high

background of non-target DNA with a sensitivity of as little as 0.01%. This assay has shown promise in detecting *IDH1* mutant mRNA in CSF-derived extracellular vesicles. Through the development of BEAMing-PCR, it was found that the copy number of *IDH1* mRNA was significantly elevated in patients with an *IDH* mutation as opposed to *IDH* wildtype control samples [184], suggesting that a greater focus on mRNA-based detection could be beneficial.

Relatedly, ddPCR has demonstrated exceptional sensitivity compared to other PCR variations such as qRT-PCR [182, 185], and has been employed for the detection of cfDNA in CSF [186] and blood [187, 188]. ddPCR is particularly advantageous for the detection of *IDH* mutations due to the water-oil emulsion partitions that allow for high sensitivity in a high background of non-target DNA. A TaqMan-based allele specific qPCR has also been employed to detect *IDH* mutations in FFPEs and blood [189], further contributing to the possibility of liquid biopsies for patients to infer the *IDH* mutational status prior to surgical resection. Due to the similar survival benefit imparted by *IDH* driver mutations, inclusivity for all known variants with PCR-based assays would be ideal but has proven difficult. Consequently, *IDH1*-R132H has historically been the primary focus as it is the most encountered mutation. Recently, a cartridge-based RT-PCR assay kit (Idylla) has been developed which qualitatively detects five of the most common codon changes for *IDH1* (R132H/C/G/S/L) and nine codon changes in *IDH2* (R140Q/L/G/W and R172K/M/G/S/W). The Idylla assay functions with an input of FFPE, has 97% agreement with sequencing results, and requires limited hands-on time for laboratory technicians [190]. With the success of Vorasidenib on less common variants such as *IDH1*-R132C, it has become increasingly urgent for assays to be inclusive and easily implemented.

In addition to PCR, isothermal amplification techniques have also been developed for the identification and characterization of *IDH* mutations. Loop-Mediated Isothermal Amplification (LAMP) is among the most popular isothermal amplification techniques due to its ability to amplify DNA or RNA in crude cell lysates, eliminating the need for a nucleic acid extraction step. Additionally, LAMP can facilitate the simple and visual interpretation of data through turbidity or colorimetric means. LAMP coupled with a peptide nucleic acid (PNA) clamping probe has been shown to facilitate the detection of *IDH1*-R132H in tumor samples within approximately 1 hour [191]. Additionally, a LAMP-based genotyping panel for *IDH1* that uses primers modified with Locked Nucleic Acids (LNA) to mediate SNV specificity has been shown to successfully identify the specific *IDH1* variant present (R132H/L/C/G/S) within 35 minutes and can be easily interpreted through absorbance or visual interpretation of colorimetric changes [192]. LAMP is particularly advantageous for the detection of *IDH* mutations because of its ability to rapidly amplify DNA in crude cell lysates, making it a viable candidate for intraoperative use.

Histological Detection

IHC using Hematoxylin and Eosin (H&E) stained tissue sections treated with monoclonal antibodies targeting *IDH1*-R132H is commonly employed for the diagnosis of *IDH1* mutations in clinical practice. Samples are typically FFPE or frozen sections; however, frozen sections have been found to yield false positives in some cases [193]. While H09 is the most widely used antibody, others exist [194-196], including a more recently developed antibody MRQ-67 which promises comparable sensitivity and specificity but less background [197, 198]. Although *IDH1* mutations in glioma are most commonly the *IDH1*-R132H variant, alternative *IDH1*-R132 SNVs, including R132S, R132L, R132G, and R132C have been observed in the molecular analysis of primary tumor samples [20, 199] (Table 1). While available monoclonal antibodies specifically target *IDH1*-R132H, cross reactivity has been observed for other *IDH* SNVs [200]. For example, MsMab-1 recognizes *IDH1*-R132H/S/G and *IDH2*-R132S/G, while MsMab-2 recognizes *IDH1*-R132L and *IDH2*-R172M [196]. This cross reactivity is not necessarily detrimental, as oncogenic variants of *IDH1/2* mutant are often treated in a similar manner; however, an antibody that is cross-reactive with all oncogenic *IDH1/2* variants without exhibiting a positive result for the wildtype would be ideal. IHC is a particularly convenient method of diagnosis for *IDH* mutations from a clinical perspective as the antibody can be applied and assessed alongside routine histological analysis often utilized to gain information about nuclear atypia, mitotic activity, microvascular proliferation, and necrosis within the tumor [201]. More

recently, artificial intelligence-based applications such as machine learning and deep learning have advanced the accuracy of histological analysis. To this end, these applications have been highly successful in differentiating between *IDH* wildtype and *IDH* mutant gliomas using digitalized whole slide images [202-206].

Table 1. Frequency of *IDH* variants in low-grade glioma based on values reported in current literature [199, 207].

<i>IDH</i> variant	Frequency in low-grade glioma (%)
<i>IDH1</i> -R132H	62.0-93.0
<i>IDH1</i> -R132C	2.9-4.3
<i>IDH1</i> -R132G	1.0-2.5
<i>IDH1</i> -R132S	1.1-2.2
<i>IDH1</i> -R132L	0.2-0.6
<i>IDH2</i> -R172K	2.8-3.0
<i>IDH2</i> -R172W	0.6
<i>IDH2</i> -R172M	0.8
<i>IDH2</i> -R172S	0.2
<i>IDH1</i> -R132P <i>IDH1</i> -R132V <i>IDH2</i> -R172T	Extremely rare

D-2-HG as a Surrogate Marker

D-2-HG is generated by hydroxyacid-oxoacid transhydrogenase and/or 3-phosphoglycerate dehydrogenase through side reactions with low catalytic efficiency [208] or as part of an anti-inflammatory response [209]. D-2-HG is subsequently broken down by D-2-HG dehydrogenase [210], maintaining relatively low levels in healthy individuals. Elevated levels of D-2-HG in body fluids can be attributed to the metabolic disorder D-2-Hydroxyglutaric aciduria [211] or oncogenic mutations to *IDH1/2*. To this end, elevated levels of D-2-HG may be utilized as a surrogate marker as an alternative to the genetic or histological elucidation of *IDH* mutational status.

D-2-HG can accumulate in *IDH* mutant tumors at a median concentration of 1,965.8 μM [117] and at elevated levels in patient CSF [212-214] (up to 109.0 μM), and blood [212, 215-217] (up to 10.9 μM). Data obtained from currently available studies show a clear and positive correlation between D-2-HG elevation in patients with *IDH* mutants in comparison to their *IDH* wildtype counterparts; however, the ideal sample type has been a topic of some debate. The ability to quantify D-2-HG in body fluids as a surrogate marker of *IDH* mutational status could revolutionize the current standard of care and allow for preoperative, intraoperative, and/or postoperative characterization. Harnessing D-2-HG for diagnostics could also facilitate remote testing for patients, as it is highly stable following exposure to excess heat [218] or several freeze-thaw cycles [213]. A current limitation of this approach is the availability of a simple, rapid, and user-friendly method for quantification. At this time, D-2-HG can be detected by liquid chromatography-mass spectroscopy (LC-MS) [212, 214], gas chromatography-mass spectroscopy (GC-MS) [219] or magnetic resonance spectroscopy (MRS) [220]. Fluorometric and colorimetric kits are also commercially available for this purpose [221], but hands-on time and price are likely limiting factors for clinical implementation. A fluorescent resonance energy transfer (FRET) based biosensor for the detection of D-2-HG has been developed [222] but is

limited by its dynamic range and use at a physiologically impossible pH of 10. A more recent FRET-based biosensor has been validated using glioma tumor samples and contrived clinical specimens, demonstrating quantification of D-2-HG within a clinically relevant range (~300 nM-100 μ M) at physiological pH [223]. FRET-based sensors are promising diagnostic tools; however, they have not yet been evaluated in a clinical setting.

While highly useful for diagnostic purposes, the use of D-2-HG as a surrogate marker can also provide valuable insight towards the effectiveness of pharmaceutical mutant IDH inhibitors such as Ivosidenib [224, 225]. This utility becomes an even greater point of interest with the outstanding efficacy of Vorasidenib [10], which is expected to receive a fast track for approval by the Food and Drug Administration (FDA). A convenient, accurate, and highly characterized tool for the quantification of D-2-HG could also provide novel insights toward the relationship between D-2-HG with *IDH* mutant cancers such as the correlation between disease burden and D-2-HG level. Additionally, the use of D-2-HG as a surrogate marker would offer significant benefits for earlier implementation of treatment as it could alert clinicians of an *IDH* mutation without the need for a tissue biopsy. Another benefit to a liquid biopsy approach is that it would be expected to indirectly identify the presence of all oncogenic *IDH1/2* mutations due to the conserved accumulation of D-2-HG across variants [226]; however, data in this respect is scarce due to the rarity of non *IDH1*-R132H variants in glioma and relatively small sample sizes of currently available studies. Future studies to validate the consistency of D-2-HG as a surrogate marker of IDH variants would be highly desirable in determining its value as a comprehensive indicator of disease. Moreover, surveying the levels of D-2-HG in a large cohort of IDH mutant glioma patients in various body fluids preoperatively, postoperatively, and through the process of treatment is needed to determine correlations, if any, with D-2-HG levels and disease burden.

In addition to liquid biopsy approaches, MRS has also shown great promise for the non-invasive detection of 2-HG, which we discuss below.

MRI

Conventional MRI is an important standard of care for gliomas, and radiologic features such as contrast enhancement and multifocality can be useful in determining the molecular characteristics of a tumor [227]. Contrast enhancement is utilized to visualize the vascularity of a structure through the administration of a contrast agent, while multifocality is the presence of multiple distinct lesions. Imaging characteristics including a higher percentage of non-contrast enhancing tumor, larger tumor size, presence of cysts, and presence of satellites has been shown to predict the presence of an *IDH* mutation with 97.5% accuracy [228]. Furthermore, *IDH* mutant tumors typically grow in a single lobe, with the most common being the frontal [229] or temporal lobe, whereas *IDH* wildtype tumors are frequently distributed between lobes [230]. Overall, the use of MRI for the elucidation of *IDH* mutational status is beneficial due to its non-invasive nature, allowing for earlier diagnosis than methods such as sequencing or IHC which require a tissue biopsy. T2-weighted imaging is one of the most common contrast sequences in MRI, and T2-weighted Fluid-attenuated inversion recovery (T2-FLAIR) is an advantageous approach because it can be performed using only standard MRI sequences to differentiate between *IDH* wildtype and *IDH* mutant astrocytomas. T2-FLAIR MRI sequences enhance the contrast between gray matter and white matter to improve the visibility of lesions [231], and the use of T2-FLAIR mismatch for detecting *IDH* mutant gliomas is based on T2 complete (or mostly complete) homogeneous hyperintense signal and attenuation of FLAIR signal intensity with a bright peripheral rim [232, 233]. Additionally, the non-contrast enhancing properties of *IDH* mutant gliomas make the T2-FLAIR mismatch sign a useful indication of *IDH* mutational status [234].

Perfusion weighted MRI (PWI) has recently gained attention for facilitating a more accurate determination of tumor grade in comparison to conventional MRI alone [235]. PWI provides information about tissue vascularization and angiogenesis [236], and the relative cerebral blood volume (rCBV). rCBV is a value that can be calculated from PWIs by determining the volume of blood in a specific quantity of brain tissue. rCBV values can serve as a powerful indication of *IDH* wildtype

vs *IDH* mutant gliomas, as recent studies have found these values to be 2-2.5 higher in *IDH* wildtype glioma samples than their *IDH* mutant counterparts [237]. PWI has also been combined with dynamic susceptibility contrast-enhanced MRI (DSC) [229]. DSC utilizes signal loss induced by paramagnetic contrast agents like gadolinium-based compounds on T2-weighted images to determine additional parameters such as relative cerebral blood flow (rCBF), and mean transit time (MTT). These parameters are subsequently used to assess regional perfusion and have been used in combination with PWI to determine the apparent diffusion coefficient (ADC). To this end, the minimum/relative ADC [229] and mean ADC [238] have been found to be significantly elevated in *IDH* mutant astrocytoma (grade II and III) compared to *IDH* wildtype tumors. These findings are supported with the use of diffusion tensor imaging (DTI) to determine the ADC of gliomas, which found that fractional anisotropy and ADC from DTI can successfully determine the *IDH1* mutational status in gliomas [239]. Diffusion weighted MRI (DWI) techniques allow for the observation of the cellular architecture of tumors and surrounding tissue [240] by assessing the Brownian motion of water molecules and have shown promise in differentiating between *IDH* wildtype and *IDH* mutant gliomas [239, 241]. DWI and PWI have also been used to assess the response of *IDH1* mutant gliomas to pharmaceutical *IDH* mutant inhibitors, where an increase in the normalized rCBV and ADC were found to be a useful indicator of antitumor response within a timeframe of 2-4 months [242]. Recently, artificial intelligence applications such as machine learning and deep learning have become valuable tools for highly accurate differentiation between *IDH* wildtype and *IDH* mutant gliomas in MRI-based applications [243-248]. Carosi et al., have also extensively covered MRI-based techniques for the detection of *IDH* mutant gliomas and other solid tumors [249].

MRS

Due to the unique accumulation of D-2-HG, *IDH* mutations may also be detected with the use of MRS through the measurement of total 2-HG [250-255]. With an *in vivo* sensitivity of approximately 1 mM and an *ex vivo* sensitivity for intact biopsies of 0.1-0.01 mM [256], MRS offers localized 2-HG quantification directly in the lesion and is well poised to differentiate between *IDH* wildtype and *IDH* mutant gliomas. D-2-HG is known to accumulate in *IDH* mutant gliomas at a median concentration of 1,965.8 μM , a value heavily contrasted by *IDH* wildtype gliomas which yield a median value of 14.0 μM [117]. 2-HG MRS has demonstrated impressive sensitivity and specificity that outperform conventional MRI as well as DWI and PWI [251]. Additionally, as D-2-HG is known to deplete in response to treatment with pharmaceutical inhibitors such as Ivosidenib [224, 225] or Vorasidenib [10], MRS is currently being explored for its ability to gauge the effectiveness of mutant *IDH* inhibitors [257]. While MRS is both highly sensitive and specific, this method may be limited by a low signal-to-noise ratio which requires lesions to be at least several milliliters in volume and sufficiently distant from fluid-brain or air-fluid interfaces. Furthermore, MRS cannot discriminate between D-2-HG and its naturally occurring enantiomer, L-2-HG. L-2-HG is not a useful indication of disease state; thus, enantiomer discrimination would add a greater level of confidence to MRS-based applications. However, analysis of total 2-HG within glioma tissues has shown a median value of 1,971.5 μM for *IDH* mutant, compared to a median value of 27.0 μM for *IDH* wildtype [117]. These results still provide a clear indication of disease state, however including larger patient populations in these types of studies are necessary to determine how much variability exists in enantiomer ratios and 2-HG concentrations.

Clinical Implications of *IDH* Mutations

Clinical Classification of Gliomas

Despite advances in diagnosis and treatment of glioma, the prognosis for the disease is poor [258]. To aid in curbing the lack of improvement in life expectancy, the medical community has increased reliance on molecular analysis of tumors. In addition to the traditional histological and immunohistological methodologies used to characterize brain tumors, the 2021 WHO CNS5 integrated molecular diagnostics for the further classification of tumors [259]. As a result, there are

six new families in the classification of gliomas to include: (1) Adult-type diffuse gliomas, (2) Pediatric-type diffuse low-grade gliomas, (3) Pediatric-type diffuse high-grade gliomas, (4) Circumscribed astrocytic gliomas, (5) Glioneuronal and neuronal, and (6) Ependymomas. The most common family of tumors, adult type diffuse gliomas, includes GBM and mutant *IDH* gliomas [260]. With this molecular classification, *IDH* mutant gliomas have been identified as a biologically distinct group of tumors. In cases of adult-type diffuse glioma, the most significant molecular prognostic indicator is *IDH* mutational status, where *IDH* mutant gliomas are less aggressive than their wildtype counterparts [261]. Molecular diagnosis is imperative as *IDH1/2* mutations are associated with a prolonged survival benefit of approximately 4-fold when molecular identification is combined with surgical resection [262, 263]. Identification of *IDH* status stratifies adult-type diffuse gliomas into separate classifications where GBM is exclusively characterized as *IDH* wildtype. Further molecular classification for wildtype GBM includes identification of one or more of the following: mutations found in the *TERT* promoter, amplification of epidermal growth factor receptor (*EGFR*) and chromosome 7 gain (partial or complete) / chromosome 10 loss. [264-267]

Separate from *IDH* wildtype GBM, mutant *IDH* gliomas are molecularly categorized into oligodendroglioma or astrocytoma. The hallmark of oligodendroglioma includes the 1p/19q codeletion, whereas *ATRX* and *p53* mutations differentiate mutant *IDH* gliomas into astrocytomas. Among gliomas with *ATRX* loss, 89% retained *IDH1/2* mutations while *ATRX* retention in *IDH1/2* mutants was strongly associated with 1p/19q loss, making this a differentiating feature associated with oligodendroglioma [268]. Further molecular characterization of the mutant *IDH* astrocytoma include detection of the presence or absence of the *CDKN2A/B* gene. Homozygous deletion of the *CDKN2A/B* gene characterizes the tumor as grade 4. Grading of mutant *IDH* astrocytomas retaining the *CDKN2A/B* gene relies on histological analysis to be differentiated into grade 2 and 3 mutant *IDH* astrocytoma. It is worth noting that astrocytomas can also be categorized as wildtype *IDH* but also retain one or more of the *TERT* promoter mutations, *EGFR* amplification and/or chromosome 7/10 aneuploidy. The classification of gliomas has also been extensively covered in a recent review by Weller et al. [269].

Influence of Mutational Status on the Production of D-2-HG

Mutant *IDH* astrocytoma has an incidence rate of 0.44 per 100,000 individuals with approximately 3,000 cases identified in the United States, making up 11% of all diffuse gliomas [260]. From a clinical perspective, *IDH* mutant gliomas have a significant survival advantage over wildtype gliomas. As identified earlier in this review, *IDH1/2* mutations lead to the accumulation of D-2-HG which has pleiotropic oncogenic effects that result in prolonged life expectancy and delayed therapeutic interventions. The overwhelming majority of this data is based on the *IDH1*-R132H mutation. However, very little is known regarding the cellular accumulation of D-2-HG for the less common mutations of *IDH1* such as R132C/G/S/L. A recent publication by Pusch et. al. performed a study evaluating the enzymatic activity of recombinant *IDH1* variants on isocitrate/ α KG substrate and found that the prevalence rate of *IDH1*-R132X variants (Table 1) found in patients is inversely proportional to their respective affinities suggesting that selective pressure (ie. D-2-HG toxicity) favor the common *IDH1*-R132H variant [270]. Based on these data, a favorable clinical outcome would be seen due to increased production of the oncometabolite, D-2-HG. Natsumeda et. al. demonstrated that elevated 2-HG had a better overall survival than lower 2-HG [271]. However, this analysis was performed using MRS in the evaluation of total 2-HG. As seen in multiple studies, *IDH1* mutant clinical patient outcomes are variable [261, 272-275]. Of significance to the prognostic implications of *IDH* mutants is the presence of sub-clonal populations with mosaic expression [276-283], confounding interpretation of the role of D-2-HG production. As a result, quantitative analysis of sub clonal populations may provide more clarity for the treatment of *IDH1* mutant gliomas.

Pharmaceutical Treatment of IDH Mutant Gliomas

Mutant *IDH* gliomas and subsequent D-2-HG production provide a highly druggable target due to its role in glioma formation and progression [284]. Early *IDH* inhibition is especially important, as

tolerable drugs could potentially delay the long-term neurocognitive toxicities of standard treatment which has been identified as detrimental factor in employment and quality of life [285, 286]. Mutant IDH inhibitors have been investigated in glioma for approximately ten years [287, 288]. Two inhibitors, Ivosidenib and Enasidenib, have been approved by the FDA for the treatment of *IDH*-mutant leukemia. The two most studied drugs in glioma are Ivosidenib (AG-120), a mutant IDH1 inhibitor, and Vorasidenib (AG-881) an IDH1/2 inhibitor [10]. Ivosidenib is a specific, reversible, allosteric competitive inhibitor of mutant IDH1, and has shown clinical utility in treating *IDH1*-mutant gliomas [10]. Vorasidenib, a pan-IDH1/IDH2 inhibitor, displays CNS penetration and successfully demonstrated itself as a potential treatment for *IDH*-mutant glioma pending FDA approval [289]. The recent phase 3 INDIGO trial evaluating Vorasidenib demonstrated significantly prolonged disease stability as well as the ability to delay additional standard therapeutic interventions [10]. More recently, a dual-inhibitor of both nicotinamide phosphoribosyl transferase (NAMPT) and mutant IDH1 has been developed which has the ability to cross the BBB and demonstrates potent efficacy *in vivo* [290]. Carosi et al., have recently provided an in-depth analysis of pharmaceuticals targeting IDH-mutant gliomas and other solid tumors [249].

In addition to pharmaceuticals that directly inhibit the mutant *IDH* protein, inhibitors that interact with proteins associated with epigenetic marks also make excellent targets. Specifically focusing on the acetylation and methylation state of chromatin, HDACs and Jumonji class demethylases are chromatin erasers that are of clinical interest. In *IDH* mutant glioma, the downstream effect of D-2-HG production inhibits α KG-dependent DNA demethylases rendering chromatin hypermethylated. HDACs are enriched in hypermethylated regions of chromatin, potentially making mutant *IDH* cells more susceptible to HDAC therapy. The HDAC inhibitor Panobinostat (Farydak) was an FDA-approved drug for the treatment of multiple myeloma that had been recognized as a potential *IDH* mutant inhibitor for gliomas [291]. Following treatment with Panobinostat, *IDH1* mutant glioma cells demonstrated increased cytotoxicity and inhibited proliferation [45]. Panobinostat was also found to compound to inhibit growth in *IDH1* mutant glioma lines [46]. Panobinostat was recently withdrawn from USA markets due to incomplete post-approval studies and inability to confirm the clinical benefits within the given constraints [292]. Of significance to Jumonji class demethylases, KDM5 has been shown to be a target of 2-HG production resulting in inhibition of lysine demethylase activity and contributes to cellular transformation in mutant *IDH* glioma [293]. Nie et. al. has described a family of pyrazolyl pyridines that have demonstrated potent activity targeting KDM5A/B resulting in an increase in H3K4me3 epigenetic marks in cancer cell lines [294].

Molecular Basis for the Improved Prognosis of IDH Mutant Gliomas

The survival advantage for gliomas retaining *IDH* mutations is poorly understood; however, potential mechanisms for this benefit are slowly being elucidated. *IDH* mutant cells demonstrate a greater degree of hypermethylation in undifferentiated neural progenitor cells than in mature astrocytes, suggesting that the epigenetic modifications within the *IDH* mutant genome are dependent upon cellular context [90]. Pursuant to this point, a recent publication identified that D-2-HG reduces glioma cell growth by inhibiting the m⁶A epi transcriptome regulator, FTO [81]. The aforementioned enzyme is responsible for m⁶A hypermethylation for a specific set of mRNA transcripts to include *ATF5* (Activating Transcription Factor 5) leading to increased cellular apoptosis. Interestingly, inhibition of FTO led to the growth characteristics of wildtype *IDH* gliomas to be more consistent with *IDH* mutant growth phenotype. Within *IDH* mutant astrocytomas, global DNA methylation status and *CDKN2A* homozygous deletion were found to be significant prognostic indicators [295]. Non-canonical mutations also play a role as a prognostic tool for gliomas. Interestingly, non-canonical *IDH1*-R132 mutations have an improved prognostic outcome compared to the canonical *IDH1*-R132H mutation in gliomas [296]. This lends support for the development of diagnostic tools capable of readily differentiating the mutational status in patients.

Clinical Trials

A comprehensive assessment of current trials targeting mutant *IDH* gliomas can be found in reviews by Sharma and Kayabolen [297, 298].

Conclusions

IDH is the most common metabolic mutation associated with oncogenesis, and the production of D-2-HG yields a unique cancer phenotype to include a characteristic epigenetic profile. *IDH* serves as a critical biomarker in hematological malignancies as well as solid tumors such as glioma, chondrosarcoma, and cholangiosarcoma. While we focus solely on gliomas in this review, Carosi et al. recently covered the role of *IDH* mutations shared by or unique to these solid tumors. The epigenetic, immunological, and metabolic characteristics are highlighted, as well as selected diagnostics and pharmaceuticals [249]. In this review, we expand upon this work to provide a highly detailed analysis of the molecular mechanism and consequences of *IDH* mutant gliomas with a special focus on the role of metabolism. D-2-HG is essential for the development and maintenance of *IDH* mutant glioma. Its inhibition of α KG-dependent dioxygenases yields a unique epigenetic profile/transcriptome reliant upon its continued production and accumulation. We provide an extensive review of current data highlighting the specific role of D-2-HG in various pathways, including m⁶A modification, DNA damage repair, metabolic rewiring, and epigenetics. In addition to the molecular mechanism of *IDH* mutations in glioma, we also extensively cover the past, present, and future directions of diagnostics that have been developed for the detection of *IDH* mutant gliomas. With the recent success of Vorasidenib [10], innovative methods capable of early detection will be increasingly imperative for improving patient prognosis.

Author Contributions: All authors contributed to the writing, revision, and editing of this manuscript.

Conflicts of interest: The authors declare that no conflicts of interest.

Abbreviation

Abbreviation	Definition
5-mC	5-methylcytosine
ABH	AlkB homologs
ADC	Apparent diffusion coefficient
α KG	α -ketoglutarate
AML	Acute myeloid leukemia
ATF	Activating transcription factor
ATM	Ataxia-telangiectasia-mutated
ATRX	Alpha thalassemia/mental retardation syndrome X-linked gene
BBB	Blood-brain barrier
BCAA	Branched-chain amino acids
BCAT (1/2)	Branched-chain aminotransferase (1 or 2)
BEAMing	Beads, emulsion, amplification, magnetics
CPE	Carboxypeptidase
CDC20	Cell division cycle 20
cfDNA	Cell-free circulating DNA
CHD (3-5)	Chromodomain helicase DNA binding protein (3-5)
CRISPR	Clustered regularly interspaced short palindromic repeats
CSF	Cerebral spinal fluid
D-2-HG	D-2-Hydroxyglutarate
ddPCR	Digital droplet PCR
DDR	DNA damage repair
DBC1	Deleted in breast cancer 1
DSB	Double-stranded break
DSC	Dynamic susceptibility contrast-enhanced MRI
DTI	Diffusion tensor imaging
DWI	Diffusion weighted MRI

EN2	Engrailed 2
EGFR	Epidermal growth factor receptor
FDA	Food and drug administration
FFPE	Formalin-fixed paraffin embedded tissue
FRET	Fluorescence resonance energy transfer
FTO	Fat mass and obesity-associated protein
G-CIMP	Glioma CpG island methylator phenotype
GBM	Glioblastoma multiforme
GC-MS	Gas chromatography mass-spectroscopy
H&E	Hematoxylin and Eosin
HDAC	Histone deacetylase
HIF	Hypoxia inducible factor
IDH	Isocitrate dehydrogenase
JmjC	Jumonji-C
KDM	Histone lysine demethylase
L-2-HG	L-2-Hydroxyglutarate
LAMP	Loop-mediated isothermal amplification
LC-MS	Liquid chromatography mass-spectroscopy
LDH (A/B)	Lactate dehydrogenase A or B
LNA	Locked nucleic acid
m6A	N6-methyladenosine
MAPK	Mitogen-activated protein kinase
MCT	Monocarboxylate transporters
MGMT	Methyl guanine methyl transferase
MRI	Magnetic resonance imaging
MRS	Magnetic resonance spectroscopy
MTT	Mean transit time
NAMPT	Nicotinamide phosphoribosyltransferase
nCATS	Nanopore Cas9 targeted sequencing
NGS	Next generation sequencing
NuRD	Nucleosome remodeling
ONT	Oxford nanopore technology
PARP	Poly(ADP) ribose
PDB	Protein data bank
PFKP	Phosphofructokinase platelet
PHD	Prolyl hydroxylase
PNA	Peptide nucleic acid
PWI	Perfusion weighted MRI
PYCR1	Proline 5-carboxylase reductase 1
qRT-PCR	Quantitative real-time PCR
rCBF	Relative cerebral blood flow
rCBV	Relative cerebral blood volume
RNAseq	RNA sequencing
SNV	Single nucleotide variant
ssRNAseq	Single cell RNA sequencing
STAT	Signal transducer and activator of transcription
T2-FLAIR	T2 fluid-attenuated inversion recovery
TERT	Telomerase reverse transcriptase
TET	Ten-eleven translocation
TMZ	Temozolomide
VAF	Variant allele frequency
VIM	Vimentin
WHO CNS5	World Health Organization central nervous system 5
WASF3	Wiskott-Aldrich syndrome protein family
ZMYND8	Zinc finger MYND-type containing 8

References

1. Ijzerman-Korevaar, Margriet, Tom J. Snijders, Alexander de Graeff, Saskia C. C. M. Teunissen, and Filip Y. F. de Vos. "Prevalence of Symptoms in Glioma Patients Throughout the Disease Trajectory: A Systematic Review." *Journal of Neuro-Oncology* 140, no. 3 (2018): 485-96.
2. Weller, Michael, Wolfgang Wick, Ken Aldape, Michael Brada, Mitchell Berger, Stefan M. Pfister, Ryo Nishikawa, Mark Rosenthal, Patrick Y. Wen, Roger Stupp, and Guido Reifenberger. "Glioma." *Nature Reviews Disease Primers* 1, no. 1 (2015): 15017.
3. Louis, D. N., A. Perry, P. Wesseling, D. J. Brat, I. A. Cree, D. Figarella-Branger, C. Hawkins, H. K. Ng, S. M. Pfister, G. Reifenberger, R. Soffietti, A. von Deimling, and D. W. Ellison. "The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary." *Neuro Oncol* 23, no. 8 (2021): 1231-51.
4. Capper, D., D. T. W. Jones, M. Sill, V. Hovestadt, D. Schrimpf, D. Sturm, C. Koelsche, F. Sahm, L. Chavez, D. E. Reuss, A. Kratz, A. K. Wefers, K. Huang, K. W. Pajtler, L. Schweizer, D. Stichel, A. Olar, N. W. Engel, K. Lindenberg, P. N. Harter, A. K. Braczynski, K. H. Plate, H. Dohmen, B. K. Garvalov, R. Coras, A. Hölsken, E. Hewer, M. Bewerunge-Hudler, M. Schick, R. Fischer, R. Beschoner, J. Schittenhelm, O. Staszewski, K. Wani, P. Varlet, M. Pages, P. Temming, D. Lohmann, F. Selt, H. Witt, T. Milde, O. Witt, E. Aronica, F. Giangaspero, E. Rushing, W. Scheurlen, C. Geisenberger, F. J. Rodriguez, A. Becker, M. Preusser, C. Haberler, R. Bjerkvig, J. Cryan, M. Farrell, M. Deckert, J. Hench, S. Frank, J. Serrano, K. Kannan, A. Tsirigos, W. Brück, S. Hofer, S. Brehmer, M. Seiz-Rosenhagen, D. Hänggi, V. Hans, S. Rozsnoki, J. R. Hansford, P. Kohlhof, B. W. Kristensen, M. Lechner, B. Lopes, C. Mawrin, R. Ketter, A. Kulozik, Z. Khatib, F. Heppner, A. Koch, A. Jouvet, C. Keohane, H. Mühleisen, W. Mueller, U. Pohl, M. Prinz, A. Benner, M. Zapatka, N. G. Gottardo, P. H. Driever, C. M. Kramm, H. L. Müller, S. Rutkowski, K. von Hoff, M. C. Frühwald, A. Gnekow, G. Fleischhack, S. Tippelt, G. Calaminus, C. M. Monoranu, A. Perry, C. Jones, T. S. Jacques, B. Radlwimmer, M. Gessi, T. Pietsch, J. Schramm, G. Schackert, M. Westphal, G. Reifenberger, P. Wesseling, M. Weller, V. P. Collins, I. Blümcke, M. Bendszus, J. Debus, A. Huang, N. Jabado, P. A. Northcott, W. Paulus, A. Gajjar, G. W. Robinson, M. D. Taylor, Z. Jaunmuktane, M. Ryzhova, M. Platten, A. Unterberg, W. Wick, M. A. Karajannis, M. Mittelbronn, T. Acker, C. Hartmann, K. Aldape, U. Schüller, R. Buslei, P. Lichter, M. Kool, C. Herold-Mende, D. W. Ellison, M. Hasselblatt, M. Snuderl, S. Brandner, A. Korshunov, A. von Deimling, and S. M. Pfister. "DNA Methylation-Based Classification of Central Nervous System Tumours." *Nature* 555, no. 7697 (2018): 469-74.
5. Boisselier, B., Y. Marie, M. Labussière, P. Ciccarino, V. Desestret, X. Wang, L. Capelle, J. Y. Delattre, and M. Sanson. "Cold Pcr Hrm: A Highly Sensitive Detection Method for Idh1 Mutations." *Hum Mutat* 31, no. 12 (2010): 1360-5.
6. Takano, Shingo, Wei Tian, Masahide Matsuda, Tetsuya Yamamoto, Eiichi Ishikawa, Mika Kato Kaneko, Kentaro Yamazaki, Yukinari Kato, and Akira Matsumura. "Detection of Idh1 Mutation in Human Gliomas: Comparison of Immunohistochemistry and Sequencing." *Brain Tumor Pathology* 28, no. 2 (2011): 115-23.
7. Han, S., Y. Liu, S. J. Cai, M. Qian, J. Ding, M. Larion, M. R. Gilbert, and C. Yang. "Idh Mutation in Glioma: Molecular Mechanisms and Potential Therapeutic Targets." *Br J Cancer* 122, no. 11 (2020): 1580-89.
8. Parsons, D. W., S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz, Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. Marie, S. M. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, and K. W. Kinzler. "An Integrated Genomic Analysis of Human Glioblastoma Multiforme." *Science* 321, no. 5897 (2008): 1807-12.
9. Popovici-Muller, J., R. M. Lemieux, E. Artin, J. O. Saunders, F. G. Salituro, J. Travins, G. Cianchetta, Z. Cai, D. Zhou, D. Cui, P. Chen, K. Straley, E. Tobin, F. Wang, M. D. David, V. Penard-Lacronique, C. Quivoron, V. Saada, S. de Botton, S. Gross, L. Dang, H. Yang, L. Utley, Y. Chen, H. Kim, S. Jin, Z. Gu, G. Yao, Z. Luo, X. Lv, C. Fang, L. Yan, A. Olaharski, L. Silverman, S. Biller, S. M. Su, and K. Yen. "Discovery of Ag-120 (Ivosidenib): A First-in-Class Mutant Idh1 Inhibitor for the Treatment of Idh1 Mutant Cancers." *ACS Med Chem Lett* 9, no. 4 (2018): 300-05.
10. Mellingshoff, I. K., M. J. van den Bent, D. T. Blumenthal, M. Touat, K. B. Peters, J. Clarke, J. Mendez, S. Yust-Katz, L. Welsh, W. P. Mason, F. Ducray, Y. Umemura, B. Nabors, M. Holdhoff, A. F. Hottinger, Y. Arakawa, J. M. Sepulveda, W. Wick, R. Soffietti, J. R. Perry, P. Giglio, M. de la Fuente, E. A. Maher, S. Schoenfeld, D. Zhao, S. S. Pandya, L. Steelman, I. Hassan, P. Y. Wen, and T. F. Cloughesy. "Vorarsidenib in Idh1- or Idh2-Mutant Low-Grade Glioma." *N Engl J Med* 389, no. 7 (2023): 589-601.
11. Amary, M. F., K. Bacsí, F. Maggiani, S. Damato, D. Halai, F. Berisha, R. Pollock, P. O'Donnell, A. Grigoriadis, T. Diss, M. Eskandarpour, N. Presneau, P. C. Hogendoorn, A. Futreal, R. Tirabosco, and A. M. Flanagan. "Idh1 and Idh2 Mutations Are Frequent Events in Central Chondrosarcoma and Central and Periosteal Chondromas but Not in Other Mesenchymal Tumours." *J Pathol* 224, no. 3 (2011): 334-43.
12. Borger, D. R., L. Goyal, T. Yau, R. T. Poon, M. Ancukiewicz, V. Deshpande, D. C. Christiani, H. M. Liebman, H. Yang, H. Kim, K. Yen, J. E. Faris, A. J. Iafrate, E. L. Kwak, J. W. Clark, J. N. Allen, L. S. Blaszkowsky, J. E. Murphy, S. K. Saha, T. S. Hong, J. Y. Wo, C. R. Ferrone, K. K. Tanabe, N. Bardeesy, K. S. Straley, S. Agresta, D. P. Schenkein, L. W. Ellisen, D. P. Ryan, and A. X. Zhu. "Circulating Oncometabolite 2-Hydroxyglutarate

- Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma." *Clin Cancer Res* 20, no. 7 (2014): 1884-90.
13. Fathi, A. T., H. Sadrzadeh, A. H. Comander, M. J. Higgins, A. Bardia, A. Perry, M. Burke, R. Silver, C. R. Matulis, K. S. Straley, K. E. Yen, S. Agresta, H. Kim, D. P. Schenkein, and D. R. Borger. "Isocitrate Dehydrogenase 1 (Idh1) Mutation in Breast Adenocarcinoma Is Associated with Elevated Levels of Serum and Urine 2-Hydroxyglutarate." *Oncologist* 19, no. 6 (2014): 602-7.
 14. Dang, L., D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger, E. M. Driggers, V. R. Fantin, H. G. Jang, S. Jin, M. C. Keenan, K. M. Marks, R. M. Prins, P. S. Ward, K. E. Yen, L. M. Liau, J. D. Rabinowitz, L. C. Cantley, C. B. Thompson, M. G. Vander Heiden, and S. M. Su. "Cancer-Associated Idh1 Mutations Produce 2-Hydroxyglutarate." *Nature* 462, no. 7274 (2009): 739-44.
 15. Raimondi, V., G. Ciotti, M. Gottardi, and F. Ciccarese. "2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies." *Biomedicines* 10, no. 6 (2022).
 16. Malta, T. M., C. F. de Souza, T. S. Sabedot, T. C. Silva, M. S. Mosella, S. N. Kalkanis, J. Snyder, A. V. B. Castro, and H. Noushmehr. "Glioma CpG Island Methylator Phenotype (G-Cimp): Biological and Clinical Implications." *Neuro Oncol* 20, no. 5 (2018): 608-20.
 17. Cui, D., J. Ren, J. Shi, L. Feng, K. Wang, T. Zeng, Y. Jin, and L. Gao. "R132h Mutation in Idh1 Gene Reduces Proliferation, Cell Survival and Invasion of Human Glioma by Downregulating Wnt/ β -Catenin Signaling." *Int J Biochem Cell Biol* 73 (2016): 72-81.
 18. Wang, H. Y., K. Tang, T. Y. Liang, W. Z. Zhang, J. Y. Li, W. Wang, H. M. Hu, M. Y. Li, H. Q. Wang, X. Z. He, Z. Y. Zhu, Y. W. Liu, and S. Z. Zhang. "The Comparison of Clinical and Biological Characteristics between Idh1 and Idh2 Mutations in Gliomas." *J Exp Clin Cancer Res* 35 (2016): 86.
 19. Liu, S., T. Cadoux-Hudson, and C. J. Schofield. "Isocitrate Dehydrogenase Variants in Cancer - Cellular Consequences and Therapeutic Opportunities." *Curr Opin Chem Biol* 57 (2020): 122-34.
 20. Gupta, R., S. Flanagan, C. C. Li, M. Lee, B. Shivalingham, S. Maleki, H. R. Wheeler, and M. E. Buckland. "Expanding the Spectrum of Idh1 Mutations in Gliomas." *Mod Pathol* 26, no. 5 (2013): 619-25.
 21. Haider, Ali S., Chibawanye I. Ene, Paolo Palmisciano, Maryam Haider, Ganesh Rao, Leomar Y. Ballester, and Gregory N. Fuller. "Concurrent Idh1 and Idh2 Mutations in Glioblastoma: A Case Report." *Frontiers in Oncology* 13 (2023).
 22. Yang, H., D. Ye, K. L. Guan, and Y. Xiong. "Idh1 and Idh2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives." *Clin Cancer Res* 18, no. 20 (2012): 5562-71.
 23. Gross, S., R. A. Cairns, M. D. Minden, E. M. Driggers, M. A. Bittinger, H. G. Jang, M. Sasaki, S. Jin, D. P. Schenkein, S. M. Su, L. Dang, V. R. Fantin, and T. W. Mak. "Cancer-Associated Metabolite 2-Hydroxyglutarate Accumulates in Acute Myelogenous Leukemia with Isocitrate Dehydrogenase 1 and 2 Mutations." *J Exp Med* 207, no. 2 (2010): 339-44.
 24. Dow, Jonathan, and Peter M. Glazer. "Chapter 11 - Oncometabolites, Epigenetic Marks, and DNA Repair." In *Epigenetics and DNA Damage*, edited by Miriam Galvonas Jasiulionis, 191-202: Academic Press, 2022.
 25. Myllyharju, Johanna. "Prolyl 4-Hydroxylases, the Key Enzymes of Collagen Biosynthesis." *Matrix Biology* 22, no. 1 (2003): 15-24.
 26. Chaumeil, M. M., P. E. Larson, S. M. Woods, L. Cai, P. Eriksson, A. E. Robinson, J. M. Lupo, D. B. Vigneron, S. J. Nelson, R. O. Pieper, J. J. Phillips, and S. M. Ronen. "Hyperpolarized [1-¹³C] Glutamate: A Metabolic Imaging Biomarker of Idh1 Mutational Status in Glioma." *Cancer Res* 74, no. 16 (2014): 4247-57.
 27. Kickingeder, Philipp, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, and Benedikt Wiestler. "Idh Mutation Status Is Associated with a Distinct Hypoxia/Angiogenesis Transcriptome Signature Which Is Non-Invasively Predictable with Rcbv Imaging in Human Glioma." *Scientific Reports* 5, no. 1 (2015): 16238.
 28. Chou, F. J., Y. Liu, F. Lang, and C. Yang. "D-2-Hydroxyglutarate in Glioma Biology." *Cells* 10, no. 9 (2021).
 29. Turcan, S., D. Rohle, A. Goenka, L. A. Walsh, F. Fang, E. Yilmaz, C. Campos, A. W. Fabius, C. Lu, P. S. Ward, C. B. Thompson, A. Kaufman, O. Guryanova, R. Levine, A. Heguy, A. Viale, L. G. Morris, J. T. Huse, I. K. Mellingshoff, and T. A. Chan. "Idh1 Mutation Is Sufficient to Establish the Glioma Hypermethylator Phenotype." *Nature* 483, no. 7390 (2012): 479-83.
 30. Sarah, Letitia, and Danica Galonić Fujimori. "Recent Developments in Catalysis and Inhibition of the Jumonji Histone Demethylases." *Current Opinion in Structural Biology* 83 (2023): 102707.
 31. Manni, Wang, Xue Jianxin, Hong Weiqi, Chen Siyuan, and Shi Huashan. "Jmjd Family Proteins in Cancer and Inflammation." *Signal Transduction and Targeted Therapy* 7, no. 1 (2022): 304.
 32. Lee, D. H., G. W. Kim, J. Yoo, S. W. Lee, Y. H. Jeon, S. Y. Kim, H. G. Kang, D. H. Kim, K. H. Chun, J. Choi, and S. H. Kwon. "Histone Demethylase Kdm4c Controls Tumorigenesis of Glioblastoma by Epigenetically Regulating P53 and C-Myc." *Cell Death Dis* 12, no. 1 (2021): 89.
 33. Yang, Guan-Jun, Ming-Hui Zhu, Xin-Jiang Lu, Yan-Jun Liu, Jian-Fei Lu, Chung-Hang Leung, Dik-Lung Ma, and Jiong Chen. "The Emerging Role of Kdm5a in Human Cancer." *Journal of Hematology & Oncology* 14, no. 1 (2021): 30.

34. Losman, J. A., P. Koivunen, and W. G. Kaelin, Jr. "2-Oxoglutarate-Dependent Dioxygenases in Cancer." *Nat Rev Cancer* 20, no. 12 (2020): 710-26.
35. Zhang, Lan, Yao Chen, Zhijia Li, Congcong Lin, Tongtong Zhang, and Guan Wang. "Development of Jmjc-Domain-Containing Histone Demethylase (Kdm2-7) Inhibitors for Cancer Therapy." *Drug Discovery Today* 28, no. 5 (2023): 103519.
36. Gunn, K., M. Myllykoski, J. Z. Cao, M. Ahmed, B. Huang, B. Rouaisnel, B. H. Diplas, M. M. Levitt, R. Looper, J. G. Doench, K. L. Ligon, H. I. Kornblum, S. K. McBrayer, H. Yan, C. Duy, L. A. Godley, P. Koivunen, and J. A. Losman. "(R)-2-Hydroxyglutarate Inhibits Kdm5 Histone Lysine Demethylases to Drive Transformation in Idh-Mutant Cancers." *Cancer Discov* 13, no. 6 (2023): 1478-97.
37. Guerra-Calderas, Lissania, Rodrigo González-Barrios, Luis A. Herrera, David Cantú de León, and Ernesto Soto-Reyes. "The Role of the Histone Demethylase Kdm4a in Cancer." *Cancer Genetics* 208, no. 5 (2015): 215-24.
38. Wang, Zhongze, Huarui Cai, Erhu Zhao, and Hongjuan Cui. "The Diverse Roles of Histone Demethylase Kdm4b in Normal and Cancer Development and Progression." *Frontiers in Cell and Developmental Biology* 9 (2022).
39. Ota, K., K. I. Tong, K. Goto, S. Tomida, A. Komuro, Z. Wang, K. Nishio, and H. Okada. "The H3k27 Demethylase, Utx, Regulates Adipogenesis in a Differentiation Stage-Dependent Manner." *PLoS One* 12, no. 3 (2017): e0173713.
40. Xu, W., H. Yang, Y. Liu, Y. Yang, P. Wang, S. H. Kim, S. Ito, C. Yang, P. Wang, M. T. Xiao, L. X. Liu, W. Q. Jiang, J. Liu, J. Y. Zhang, B. Wang, S. Frye, Y. Zhang, Y. H. Xu, Q. Y. Lei, K. L. Guan, S. M. Zhao, and Y. Xiong. "Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α -Ketoglutarate-Dependent Dioxygenases." *Cancer Cell* 19, no. 1 (2011): 17-30.
41. Miller, J. L., and P. A. Grant. "The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans." *Subcell Biochem* 61 (2013): 289-317.
42. Laukka, Tuomas, Matti Myllykoski, Ryan E. Looper, and Peppi Koivunen. "Cancer-Associated 2-Oxoglutarate Analogues Modify Histone Methylation by Inhibiting Histone Lysine Demethylases." *Journal of Molecular Biology* 430, no. 18, Part B (2018): 3081-92.
43. Chen, H. P., Y. T. Zhao, and T. C. Zhao. "Histone Deacetylases and Mechanisms of Regulation of Gene Expression." *Crit Rev Oncog* 20, no. 1-2 (2015): 35-47.
44. Feng, Q., and Y. Zhang. "The Mecp1 Complex Represses Transcription through Preferential Binding, Remodeling, and Deacetylating Methylated Nucleosomes." *Genes Dev* 15, no. 7 (2001): 827-32.
45. Sears, T. K., C. M. Horbinski, and K. D. Woolard. "Idh1 Mutant Glioma Is Preferentially Sensitive to the Hdac Inhibitor Panobinostat." *J Neurooncol* 154, no. 2 (2021): 159-70.
46. Garrett, Matthew C., Rebecca Albano, Troy Carnwath, Lubayna Elahi, Catherine A. Behrmann, Merissa Pemberton, Daniel Woo, Eric O'Brien, Brett VanCauwenbergh, John Perentesis, Sanjit Shah, Matthew Hagan, Ady Kendler, Chuntao Zhao, Aditi Paranjpe, Krishna Roskin, Harley Kornblum, David R. Plas, and Q. Richard Lu. "Hdac1 and Hdac6 Are Essential for Driving Growth in Idh1 Mutant Glioma." *Scientific Reports* 13, no. 1 (2023): 12433.
47. Zhang, Xinchao, Yue Zhang, Chaofu Wang, and Xu Wang. "Tet (Ten-Eleven Translocation) Family Proteins: Structure, Biological Functions and Applications." *Signal Transduction and Targeted Therapy* 8, no. 1 (2023): 297.
48. Gerecke, Christian, Caue Egea Rodrigues, Thomas Homann, and Burkhard Kleuser. "The Role of Ten-Eleven Translocation Proteins in Inflammation." *Frontiers in Immunology* 13 (2022).
49. Bogdanović, O., A. H. Smits, E. de la Calle Mustienes, J. J. Tena, E. Ford, R. Williams, U. Senanayake, M. D. Schultz, S. Hontelez, I. van Kruijsbergen, T. Rayon, F. Gnerlich, T. Carell, G. J. Veenstra, M. Manzanares, T. Sauka-Spengler, J. R. Ecker, M. Vermeulen, J. L. Gómez-Skarmeta, and R. Lister. "Active DNA Demethylation at Enhancers during the Vertebrate Phylotypic Period." *Nat Genet* 48, no. 4 (2016): 417-26.
50. Sanstead, P. J., B. Ashwood, Q. Dai, C. He, and A. Tokmakoff. "Oxidized Derivatives of 5-Methylcytosine Alter the Stability and Dehybridization Dynamics of Duplex DNA." *J Phys Chem B* 124, no. 7 (2020): 1160-74.
51. Vasanthakumar, A., and L. A. Godley. "5-Hydroxymethylcytosine in Cancer: Significance in Diagnosis and Therapy." *Cancer Genet* 208, no. 5 (2015): 167-77.
52. Johnson, Kevin C., E. Andres Houseman, Jessica E. King, Katharine M. von Herrmann, Camilo E. Fadul, and Brock C. Christensen. "5-Hydroxymethylcytosine Localizes to Enhancer Elements and Is Associated with Survival in Glioblastoma Patients." *Nature Communications* 7, no. 1 (2016): 13177.
53. Nomura, Masashi, Kuniaki Saito, Koki Aihara, Genta Nagae, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Shiro Fukuda, Takayoshi Umeda, Shota Tanaka, Shunsaku Takayanagi, Ryohei Otani, Takahide Nejo, Taijun Hana, Satoshi Takahashi, Yosuke Kitagawa, Mayu Omata, Fumi Higuchi, Taishi Nakamura, Yoshihiro Muragaki, Yoshitaka Narita, Motoo Nagane, Ryo Nishikawa, Keisuke Ueki, Nobuhito Saito, Hiroyuki Aburatani, and Akitake Mukasa. "DNA Demethylation Is Associated with Malignant Progression of Lower-Grade Gliomas." *Scientific Reports* 9, no. 1 (2019): 1903.

54. Chou, Wen-Chien, Sheng-Chieh Chou, Chieh-Yu Liu, Chien-Yuan Chen, Hsin-An Hou, Yuan-Yeh Kuo, Ming-Cheng Lee, Bor-Sheng Ko, Jih-Luh Tang, Ming Yao, Woei Tsay, Shang-Ju Wu, Shang-Yi Huang, Szu-Chun Hsu, Yao-Chang Chen, Yi-Chang Chang, Yi-Yi Kuo, Kuan-Ting Kuo, Fen-Yu Lee, Ming-Chi Liu, Chia-Wen Liu, Mei-Hsuan Tseng, Chi-Fei Huang, and Hwei-Fang Tien. "Tet2 Mutation Is an Unfavorable Prognostic Factor in Acute Myeloid Leukemia Patients with Intermediate-Risk Cytogenetics." *Blood* 118, no. 14 (2011): 3803-10.
55. Bray, Julie K., Meelad M. Dawlaty, Amit Verma, and Anirban Maitra. "Roles and Regulations of Tet Enzymes in Solid Tumors." *Trends in Cancer* 7, no. 7 (2021): 635-46.
56. Figueroa, M. E., O. Abdel-Wahab, C. Lu, P. S. Ward, J. Patel, A. Shih, Y. Li, N. Bhagwat, A. Vasanthakumar, H. F. Fernandez, M. S. Tallman, Z. Sun, K. Wolniak, J. K. Peeters, W. Liu, S. E. Choe, V. R. Fantin, E. Paietta, B. Löwenberg, J. D. Licht, L. A. Godley, R. Delwel, P. J. Valk, C. B. Thompson, R. L. Levine, and A. Melnick. "Leukemic Idh1 and Idh2 Mutations Result in a Hypermethylation Phenotype, Disrupt Tet2 Function, and Impair Hematopoietic Differentiation." *Cancer Cell* 18, no. 6 (2010): 553-67.
57. Huang, Y., J. Wei, X. Huang, W. Zhou, Y. Xu, D. H. Deng, and P. Cheng. "Comprehensively Analyze the Expression and Prognostic Role for Ten-Eleven Translocations (Tets) in Acute Myeloid Leukemia." *Transl Cancer Res* 9, no. 11 (2020): 7259-83.
58. Laukka, T., C. J. Mariani, T. Ihantola, J. Z. Cao, J. Hokkanen, W. G. Kaelin, Jr., L. A. Godley, and P. Koivunen. "Fumarate and Succinate Regulate Expression of Hypoxia-Inducible Genes Via Tet Enzymes." *J Biol Chem* 291, no. 8 (2016): 4256-65.
59. Intlekofer, A. M., R. G. Dematteo, S. Venneti, L. W. Finley, C. Lu, A. R. Judkins, A. S. Rustenburg, P. B. Grinaway, J. D. Chodera, J. R. Cross, and C. B. Thompson. "Hypoxia Induces Production of L-2-Hydroxyglutarate." *Cell Metab* 22, no. 2 (2015): 304-11.
60. Belle, Roman, Hilal Saraç, Eidarus Salah, Bhaskar Bhushan, Aleksandra Szykowska, Grace Roper, Anthony Tumber, Skirmantas Kriaucionis, Nicola Burgess-Brown, Christopher J. Schofield, Tom Brown, and Akane Kawamura. "Focused Screening Identifies Different Sensitivities of Human Tet Oxygenases to the Oncometabolite 2-Hydroxyglutarate." *Journal of Medicinal Chemistry* 67, no. 6 (2024): 4525-40.
61. Yue, X., and A. Rao. "Tet Family Dioxygenases and the Tet Activator Vitamin C in Immune Responses and Cancer." *Blood* 136, no. 12 (2020): 1394-401.
62. Gerecke, Christian, Fabian Schumacher, Alide Berndzen, Thomas Homann, and Burkhard Kleuser. "Vitamin C in Combination with Inhibition of Mutant Idh1 Synergistically Activates Tet Enzymes and Epigenetically Modulates Gene Silencing in Colon Cancer Cells." *Epigenetics* 15, no. 3 (2020): 307-22.
63. Kusi, M., M. Zand, L. L. Lin, M. Chen, A. Lopez, C. L. Lin, C. M. Wang, N. D. Lucio, N. B. Kirma, J. Ruan, T. H. Huang, and K. Mitsuya. "2-Hydroxyglutarate Destabilizes Chromatin Regulatory Landscape and Lineage Fidelity to Promote Cellular Heterogeneity." *Cell Rep* 38, no. 2 (2022): 110220.
64. Sasaki, M., C. B. Knobbe, M. Isumi, A. J. Elia, I. S. Harris, Chio, Il, R. A. Cairns, S. McCracken, A. Wakeham, J. Haight, A. Y. Ten, B. Snow, T. Ueda, S. Inoue, K. Yamamoto, M. Ko, A. Rao, K. E. Yen, S. M. Su, and T. W. Mak. "D-2-Hydroxyglutarate Produced by Mutant Idh1 Perturbs Collagen Maturation and Basement Membrane Function." *Genes Dev* 26, no. 18 (2012): 2038-49.
65. Intlekofer, A. M., and L. W. S. Finley. "Metabolic Signatures of Cancer Cells and Stem Cells." *Nat Metab* 1, no. 2 (2019): 177-88.
66. Frost, J., M. Frost, M. Batie, H. Jiang, and S. Rocha. "Roles of Hif and 2-Oxoglutarate-Dependent Dioxygenases in Controlling Gene Expression in Hypoxia." *Cancers (Basel)* 13, no. 2 (2021).
67. D'Ignazio, L., M. Batie, and S. Rocha. "Hypoxia and Inflammation in Cancer, Focus on Hif and Nf-kb." *Biomedicines* 5, no. 2 (2017).
68. Rocha, S. "Gene Regulation under Low Oxygen: Holding Your Breath for Transcription." *Trends Biochem Sci* 32, no. 8 (2007): 389-97.
69. Koivunen, P., S. Lee, C. G. Duncan, G. Lopez, G. Lu, S. Ramkissoon, J. A. Losman, P. Joensuu, U. Bergmann, S. Gross, J. Travins, S. Weiss, R. Looper, K. L. Ligon, R. G. Verhaak, H. Yan, and W. G. Kaelin, Jr. "Transformation by the (R)-Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation." *Nature* 483, no. 7390 (2012): 484-8.
70. Majmundar, A. J., W. J. Wong, and M. C. Simon. "Hypoxia-Inducible Factors and the Response to Hypoxic Stress." *Mol Cell* 40, no. 2 (2010): 294-309.
71. Böttcher, M., K. Renner, R. Berger, K. Mentz, S. Thomas, Z. E. Cardenas-Conejo, K. Dettmer, P. J. Oefner, A. Mackensen, M. Kreutz, and D. Mougiakakos. "D-2-Hydroxyglutarate Interferes with Hif-1 α Stability Skewing T-Cell Metabolism Towards Oxidative Phosphorylation and Impairing Th17 Polarization." *Oncoimmunology* 7, no. 7 (2018): e1445454.
72. Kuiper, C., G. U. Dachs, M. J. Currie, and M. C. Vissers. "Intracellular Ascorbate Enhances Hypoxia-Inducible Factor (Hif)-Hydroxylase Activity and Preferentially Suppresses the Hif-1 Transcriptional Response." *Free Radic Biol Med* 69 (2014): 308-17.
73. Miles, S. L., A. P. Fischer, S. J. Joshi, and R. M. Niles. "Ascorbic Acid and Ascorbate-2-Phosphate Decrease Hif Activity and Malignant Properties of Human Melanoma Cells." *BMC Cancer* 15 (2015): 867.

74. Chowdhury, R., K. K. Yeoh, Y. M. Tian, L. Hillringhaus, E. A. Bagg, N. R. Rose, I. K. Leung, X. S. Li, E. C. Woon, M. Yang, M. A. McDonough, O. N. King, I. J. Clifton, R. J. Klose, T. D. Claridge, P. J. Ratcliffe, C. J. Schofield, and A. Kawamura. "The Oncometabolite 2-Hydroxyglutarate Inhibits Histone Lysine Demethylases." *EMBO Rep* 12, no. 5 (2011): 463-9.
75. Zhao, S., Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K. L. Guan, and Y. Xiong. "Glioma-Derived Mutations in Idh1 Dominantly Inhibit Idh1 Catalytic Activity and Induce Hif-1alpha." *Science* 324, no. 5924 (2009): 261-5.
76. Selak, M. A., S. M. Armour, E. D. MacKenzie, H. Boulahbel, D. G. Watson, K. D. Mansfield, Y. Pan, M. C. Simon, C. B. Thompson, and E. Gottlieb. "Succinate Links Tca Cycle Dysfunction to Oncogenesis by Inhibiting Hif-Alpha Prolyl Hydroxylase." *Cancer Cell* 7, no. 1 (2005): 77-85.
77. Isaacs, J. S., Y. J. Jung, D. R. Mole, S. Lee, C. Torres-Cabala, Y. L. Chung, M. Merino, J. Trepel, B. Zbar, J. Toro, P. J. Ratcliffe, W. M. Linehan, and L. Neckers. "Hif Overexpression Correlates with Biallelic Loss of Fumarate Hydratase in Renal Cancer: Novel Role of Fumarate in Regulation of Hif Stability." *Cancer Cell* 8, no. 2 (2005): 143-53.
78. Hong, Juyeong, Kexin Xu, and Ji Hoon Lee. "Biological Roles of the Rna M6a Modification and Its Implications in Cancer." *Experimental & Molecular Medicine* 54, no. 11 (2022): 1822-32.
79. Huang, Huilin, Hengyou Weng, and Jianjun Chen. "M6a Modification in Coding and Non-Coding Rnas: Roles and Therapeutic Implications in Cancer." *Cancer Cell* 37, no. 3 (2020): 270-88.
80. Tang, Feng, Zhiyong Pan, Yi Wang, Tian Lan, Mengyue Wang, Fengping Li, Wei Quan, Zhenyuan Liu, Zefen Wang, and Zhiqiang Li. "Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma." *Neuroscience Bulletin* 38, no. 9 (2022): 1069-84.
81. Pianka, Sean T., Tie Li, Terry J. Prins, Blaine S.C. Eldred, Bryan M. Kevan, Haowen Liang, Serendipity Zapanta Rinonos, Harley I. Kornblum, David A. Nathanson, Matteo Pellegrini, Linda M. Liao, Phioanh Leia Nghiemphu, Timothy F. Cloughesy, and Albert Lai. "D-2-Hg Inhibits Idh1mut Glioma Growth Via Fto Inhibition and Resultant M6a Hypermethylation." *Cancer Research Communications* 4, no. 3 (2024): 876-94.
82. Gao, Yuan, Xiwu Ouyang, Li Zuo, Yao Xiao, Yin Sun, Chawnshang Chang, Xihu Qin, and Shuyuan Yeh. "R-2hg Downregulates Era to Inhibit Cholangiocarcinoma Via the Fto/M6a-Methylated Era/Mir16-5p/Yap1 Signal Pathway." *Molecular Therapy - Oncolytics* 23 (2021): 65-81.
83. Su, Rui, Lei Dong, Chenying Li, Sigrid Nachtergaele, Mark Wunderlich, Ying Qing, Xiaolan Deng, Yungui Wang, Xiaocheng Weng, Chao Hu, Mengxia Yu, Jennifer Skibbe, Qing Dai, Dongling Zou, Tong Wu, Kangkang Yu, Hengyou Weng, Huilin Huang, Kyle Ferchen, Xi Qin, Bin Zhang, Jun Qi, Atsuo T. Sasaki, David R. Plas, James E. Bradner, Minjie Wei, Guido Marcucci, Xi Jiang, James C. Mulloy, Jie Jin, Chuan He, and Jianjun Chen. "R-2hg Exhibits Anti-Tumor Activity by Targeting Fto/M6a/Myc/Cebpa Signaling." *Cell* 172, no. 1 (2018): 90-105.e23.
84. Qing, Ying, Lei Dong, Lei Gao, Chenying Li, Yangchan Li, Li Han, Emily Prince, Brandon Tan, Xiaolan Deng, Collin Wetzel, Chao Shen, Min Gao, Zhenhua Chen, Wei Li, Bin Zhang, Daniel Braas, Johanna ten Hoeve, Gerardo Javier Sanchez, Huiying Chen, Lai N. Chan, Chun-Wei Chen, David Ann, Lei Jiang, Markus Mueschen, Guido Marcucci, David R. Plas, Zejuan Li, Rui Su, and Jianjun Chen. "R-2-Hydroxyglutarate Attenuates Aerobic Glycolysis in Leukemia by Targeting the Fto/M6a/Pfkl/Ldhd Axis." *Molecular Cell* 81, no. 5 (2021): 922-39.e9.
85. He, C., S. Sidoli, R. Warneford-Thomson, D. C. Tatomer, J. E. Wilusz, B. A. Garcia, and R. Bonasio. "High-Resolution Mapping of Rna-Binding Regions in the Nuclear Proteome of Embryonic Stem Cells." *Mol Cell* 64, no. 2 (2016): 416-30.
86. Delatte, B., F. Wang, L. V. Ngoc, E. Collignon, E. Bonvin, R. Deplus, E. Calonne, B. Hassabi, P. Putmans, S. Awe, C. Wetzel, J. Kreher, R. Soin, C. Creppe, P. A. Limbach, C. Gueydan, V. Kruys, A. Brehm, S. Minakhina, M. Defrance, R. Steward, and F. Fuks. "Rna Biochemistry. Transcriptome-Wide Distribution and Function of Rna Hydroxymethylcytosine." *Science* 351, no. 6270 (2016): 282-5.
87. Shen, Q., Q. Zhang, Y. Shi, Q. Shi, Y. Jiang, Y. Gu, Z. Li, X. Li, K. Zhao, C. Wang, N. Li, and X. Cao. "Tet2 Promotes Pathogen Infection-Induced Myelopoiesis through Mrna Oxidation." *Nature* 554, no. 7690 (2018): 123-27.
88. Tran, Paul M. H., Lynn K. H. Tran, John Nechtman, Bruno dos Santos, Sharad Purohit, Khaled Bin Satter, Boying Dun, Ravindra Kolhe, Suash Sharma, Roni Bollag, and Jin-Xiong She. "Comparative Analysis of Transcriptomic Profile, Histology, and Idh Mutation for Classification of Gliomas." *Scientific Reports* 10, no. 1 (2020): 20651.
89. Cheng, Wen, Xiufang Ren, Chuanbao Zhang, Jinqun Cai, Sheng Han, and Anhua Wu. "Gene Expression Profiling Stratifies Idh1-Mutant Glioma with Distinct Prognoses." *Molecular Neurobiology* 54, no. 8 (2017): 5996-6005.
90. Unruh, Dusten, Makda Zewde, Adam Buss, Michael R. Drumm, Anh N. Tran, Denise M. Scholtens, and Craig Horbinski. "Methylation and Transcription Patterns Are Distinct in Idh Mutant Gliomas Compared to Other Idh Mutant Cancers." *Scientific Reports* 9, no. 1 (2019): 8946.

91. Alzial, G., O. Renoult, F. Paris, C. Gratas, A. Clavreul, and C. Pecqueur. "Wild-Type Isocitrate Dehydrogenase under the Spotlight in Glioblastoma." *Oncogene* 41, no. 5 (2022): 613-21.
92. Metallo, C. M., P. A. Gameiro, E. L. Bell, K. R. Mattaini, J. Yang, K. Hiller, C. M. Jewell, Z. R. Johnson, D. J. Irvine, L. Guarente, J. K. Kelleher, M. G. Vander Heiden, O. Iliopoulos, and G. Stephanopoulos. "Reductive Glutamine Metabolism by Idh1 Mediates Lipogenesis under Hypoxia." *Nature* 481, no. 7381 (2011): 380-4.
93. Mullen, A. R., W. W. Wheaton, E. S. Jin, P. H. Chen, L. B. Sullivan, T. Cheng, Y. Yang, W. M. Linehan, N. S. Chandel, and R. J. DeBerardinis. "Reductive Carboxylation Supports Growth in Tumour Cells with Defective Mitochondria." *Nature* 481, no. 7381 (2011): 385-8.
94. Fan, J., X. Teng, L. Liu, K. R. Mattaini, R. E. Looper, M. G. Vander Heiden, and J. D. Rabinowitz. "Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite D-2-Hydroxyglutarate." *ACS Chem Biol* 10, no. 2 (2015): 510-6.
95. Zhou, L., Z. Wang, C. Hu, C. Zhang, P. Kovatcheva-Datchary, D. Yu, S. Liu, F. Ren, X. Wang, Y. Li, X. Hou, H. Piao, X. Lu, Y. Zhang, and G. Xu. "Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with Idh1 Mutation." *J Proteome Res* 18, no. 3 (2019): 960-69.
96. Fendt, S. M. "100 Years of the Warburg Effect: A Cancer Metabolism Endeavor." *Cell* 187, no. 15 (2024): 3824-28.
97. Khurshed, M., R. J. Molenaar, K. Lenting, W. P. Leenders, and C. J. F. van Noorden. "In Silico Gene Expression Analysis Reveals Glycolysis and Acetate Anaplerosis in Idh1 Wild-Type Glioma and Lactate and Glutamate Anaplerosis in Idh1-Mutated Glioma." *Oncotarget* 8, no. 30 (2017): 49165-77.
98. Chesnelong, C., M. M. Chaumeil, M. D. Blough, M. Al-Najjar, O. D. Stechishin, J. A. Chan, R. O. Pieper, S. M. Ronen, S. Weiss, H. A. Luchman, and J. G. Cairncross. "Lactate Dehydrogenase Silencing in Idh Mutant Gliomas." *Neuro Oncol* 16, no. 5 (2014): 686-95.
99. Chaumeil, M. M., M. Radoul, C. Najac, P. Eriksson, P. Viswanath, M. D. Blough, C. Chesnelong, H. A. Luchman, J. G. Cairncross, and S. M. Ronen. "Hyperpolarized (¹³C) MR Imaging Detects No Lactate Production in Mutant Idh1 Gliomas: Implications for Diagnosis and Response Monitoring." *Neuroimage Clin* 12 (2016): 180-9.
100. Dekker, L. J. M., S. Wu, C. Jurriens, D. A. N. Mustafa, F. Grevers, P. C. Burgers, P. A. E. Sillevius Smitt, J. M. Kros, and T. M. Luider. "Metabolic Changes Related to the Idh1 Mutation in Gliomas Preserve Tca-Cycle Activity: An Investigation at the Protein Level." *FASEB J* 34, no. 3 (2020): 3646-57.
101. Arnold, P. K., and L. W. S. Finley. "Regulation and Function of the Mammalian Tricarboxylic Acid Cycle." *J Biol Chem* 299, no. 2 (2023): 102838.
102. Biedermann, J., M. Preussler, M. Conde, M. Peitzsch, S. Richter, R. Wiedemuth, K. Abou-El-Ardat, A. Krüger, M. Meinhardt, G. Schackert, W. P. Leenders, C. Herold-Mende, S. P. Niclou, R. Bjerkvig, G. Eisenhofer, A. Temme, M. Seifert, L. A. Kunz-Schughart, E. Schröck, and B. Klink. "Mutant Idh1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin." *Cancers (Basel)* 11, no. 12 (2019).
103. Fack, F., S. Tardito, G. Hochart, A. Oudin, L. Zheng, S. Fritah, A. Golebiewska, P. V. Nazarov, A. Bernard, A. C. Hau, O. Keunen, W. Leenders, M. Lund-Johansen, J. Stauber, E. Gottlieb, R. Bjerkvig, and S. P. Niclou. "Altered Metabolic Landscape in Idh-Mutant Gliomas Affects Phospholipid, Energy, and Oxidative Stress Pathways." *EMBO Mol Med* 9, no. 12 (2017): 1681-95.
104. Izquierdo-Garcia, J. L., L. M. Cai, M. M. Chaumeil, P. Eriksson, A. E. Robinson, R. O. Pieper, J. J. Phillips, and S. M. Ronen. "Glioma Cells with the Idh1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase." *PLoS One* 9, no. 9 (2014): e108289.
105. Lenting, K., M. Khurshed, T. H. Peeters, Cnam van den Heuvel, S. A. M. van Lith, T. de Bitter, W. Hendriks, P. N. Span, R. J. Molenaar, D. Botman, K. Verrijp, A. Heerschap, M. Ter Laan, B. Kusters, A. van Ewijk, M. A. Huynen, C. J. F. van Noorden, and W. P. J. Leenders. "Isocitrate Dehydrogenase 1-Mutated Human Gliomas Depend on Lactate and Glutamate to Alleviate Metabolic Stress." *FASEB J* 33, no. 1 (2019): 557-71.
106. Dekker, L. J. M., C. Verheul, N. Wensveen, W. Leenders, M. L. M. Lamfers, S. Leenstra, and T. M. Luider. "Effects of the Idh1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures." *ACS Omega* 7, no. 4 (2022): 3568-78.
107. McBrayer, S. K., J. R. Mayers, G. J. DiNatale, D. D. Shi, J. Khanal, A. A. Chakraborty, K. A. Sarosiek, K. J. Briggs, A. K. Robbins, T. Sewastianik, S. J. Shareef, B. A. Olenchock, S. J. Parker, K. Tateishi, J. B. Spinelli, M. Islam, M. C. Haigis, R. E. Looper, K. L. Ligon, B. E. Bernstein, R. D. Carrasco, D. P. Cahill, J. M. Asara, C. M. Metallo, N. H. Yennawar, M. G. Vander Heiden, and W. G. Kaelin, Jr. "Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma." *Cell* 175, no. 1 (2018): 101-16 e25.
108. Tonjes, M., S. Barbus, Y. J. Park, W. Wang, M. Schlotter, A. M. Lindroth, S. V. Pleier, A. H. C. Bai, D. Karra, R. M. Piro, J. Felsberg, A. Addington, D. Lemke, I. Weibrecht, V. Hovestadt, C. G. Rolli, B. Campos, S. Turcan, D. Sturm, ..., and B. Radlwimmer. "Bcat1 Promotes Cell Proliferation through Amino Acid Catabolism in Gliomas Carrying Wild-Type Idh1." *Nat Med* 19, no. 7 (2013): 901-08.

109. Yang, M., and K. H. Vousden. "Serine and One-Carbon Metabolism in Cancer." *Nat Rev Cancer* 16, no. 10 (2016): 650-62.
110. Hollinshead, K. E. R., H. Munford, K. L. Eales, C. Bardella, C. Li, C. Escribano-Gonzalez, A. Thakker, Y. Nonnenmacher, K. Kluckova, M. Jeeves, R. Murren, F. Cuzzo, D. Ye, G. Laurenti, W. Zhu, K. Hiller, D. J. Hodson, W. Hua, I. P. Tomlinson, ..., and D. A. Tennant. "Oncogenic Idh1 Mutations Promote Enhanced Proline Synthesis through Pycr1 to Support the Maintenance of Mitochondrial Redox Homeostasis." *Cell Rep* 22, no. 12 (2018): 3107-14.
111. Gelman, S. J., F. Naser, N. G. Mahieu, L. D. McKenzie, G. P. Dunn, M. G. Chheda, and G. J. Patti. "Consumption of Nadph for 2-Hg Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress." *Cell Rep* 22, no. 2 (2018): 512-22.
112. Badur, M. G., T. Muthusamy, S. J. Parker, S. Ma, S. K. McBrayer, T. Cordes, J. H. Magana, K. L. Guan, and C. M. Metallo. "Oncogenic R132 Idh1 Mutations Limit Nadph for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells." *Cell Rep* 25, no. 6 (2018): 1680.
113. Esmaeili, M., B. C. Hamans, A. C. Navis, R. van Horssen, T. F. Bathen, I. S. Gribbestad, W. P. Leenders, and A. Heerschap. "Idh1 R132h Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma." *Cancer Res* 74, no. 17 (2014): 4898-907.
114. Izquierdo-Garcia, J. L., P. Viswanath, P. Eriksson, M. M. Chaumeil, R. O. Pieper, J. J. Phillips, and S. M. Ronen. "Metabolic Reprogramming in Mutant Idh1 Glioma Cells." *PLoS One* 10, no. 2 (2015): e0118781.
115. Fedeles, B. I., V. Singh, J. C. Delaney, D. Li, and J. M. Essigmann. "The Alkb Family of Fe(Ii)/ α -Ketoglutarate-Dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond." *J Biol Chem* 290, no. 34 (2015): 20734-42.
116. Chen, Fangyi, Ke Bian, Qi Tang, Bogdan I. Fedeles, Vipender Singh, Zachary T. Humulock, John M. Essigmann, and Deyu Li. "Oncometabolites D- and L-2-Hydroxyglutarate Inhibit the Alkb Family DNA Repair Enzymes under Physiological Conditions." *Chemical research in toxicology* 30, no. 4 (2017): 1102-10.
117. Sim, H. W., R. Nejad, W. Zhang, F. Nassiri, W. Mason, K. D. Aldape, G. Zadeh, and E. X. Chen. "Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas." *Clin Cancer Res* 25, no. 11 (2019): 3366-73.
118. Wang, P., J. Wu, S. Ma, L. Zhang, J. Yao, K. A. Hoadley, M. D. Wilkerson, C. M. Perou, K. L. Guan, D. Ye, and Y. Xiong. "Oncometabolite D-2-Hydroxyglutarate Inhibits Alkbh DNA Repair Enzymes and Sensitizes Idh Mutant Cells to Alkylating Agents." *Cell Rep* 13, no. 11 (2015): 2353-61.
119. Lin, L., J. Cai, Z. Tan, X. Meng, R. Li, Y. Li, and C. Jiang. "Mutant Idh1 Enhances Temozolomide Sensitivity Via Regulation of the Atm/Chk2 Pathway in Glioma." *Cancer Res Treat* 53, no. 2 (2021): 367-77.
120. Matsuoka, S., G. Rotman, A. Ogawa, Y. Shiloh, K. Tamai, and S. J. Elledge. "Ataxia Telangiectasia-Mutated Phosphorylates Chk2 in Vivo and in Vitro." *Proc Natl Acad Sci U S A* 97, no. 19 (2000): 10389-94.
121. Inoue, S., W. Y. Li, A. Tseng, I. Beeran, A. J. Elia, S. C. Bendall, F. Lemonnier, K. J. Kron, D. W. Cescon, Z. Hao, E. F. Lind, N. Takayama, A. C. Planello, S. Y. Shen, A. H. Shih, D. M. Larsen, Q. Li, B. E. Snow, A. Wakeham, J. Haight, C. Gorrini, C. Bassi, K. L. Thu, K. Murakami, A. R. Elford, T. Ueda, K. Straley, K. E. Yen, G. Melino, L. Cimmino, I. Aifantis, R. L. Levine, D. D. De Carvalho, M. Lupien, D. J. Rossi, G. P. Nolan, R. A. Cairns, and T. W. Mak. "Mutant Idh1 Downregulates Atm and Alters DNA Repair and Sensitivity to DNA Damage Independent of Tet2." *Cancer Cell* 30, no. 2 (2016): 337-48.
122. Carney, S. V., K. Banerjee, A. Mujeeb, B. Zhu, S. Haase, M. L. Varela, P. Kadiyala, C. E. Tronrud, Z. Zhu, D. Mukherji, P. Gorla, Y. Sun, R. Tagett, F. J. Núñez, M. Luo, W. Luo, M. Ljungman, Y. Liu, Z. Xia, A. Schwendeman, T. Qin, M. A. Sartor, J. F. Costello, D. P. Cahill, P. R. Lowenstein, and M. G. Castro. "Zinc Finger Mynd-Type Containing 8 (Zmynd8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (Idh1) Glioma to Promote Radioresistance." *Clin Cancer Res* 29, no. 9 (2023): 1763-82.
123. Jia, Pan, Xiang Li, Xuelei Wang, Liangjiao Yao, Yingying Xu, Yu Hu, Wenwen Xu, Zhe He, Qifan Zhao, Yicong Deng, Yi Zang, Meiyu Zhang, Yan Zhang, Jun Qin, and Wei Lu. "Zmynd8 Mediated Liquid Condensates Spatiotemporally Decommission the Latent Super-Enhancers during Macrophage Polarization." *Nature Communications* 12, no. 1 (2021): 6535.
124. Spruijt, C. G., M. S. Luijsterburg, R. Menafra, R. G. Lindeboom, P. W. Jansen, R. R. Edupuganti, M. P. Baltissen, W. W. Wiegant, M. C. Voelker-Albert, F. Matarese, A. Mensinga, I. Poser, H. R. Vos, H. G. Stunnenberg, H. van Attikum, and M. Vermeulen. "Zmynd8 Co-Localizes with Nurd on Target Genes and Regulates Poly(Adp-Ribose)-Dependent Recruitment of Gatad2a/Nurd to Sites of DNA Damage." *Cell Rep* 17, no. 3 (2016): 783-98.
125. Majd, Nazanin, Timothy A. Yap, W. K. Alfred Yung, and John de Groot. "The Promise of Poly(Adp-Ribose) Polymerase (Parp) Inhibitors in Gliomas." *Journal of Immunotherapy and Precision Oncology* 3, no. 4 (2020): 157-64.
126. Garrett, M., J. Sperry, D. Braas, W. Yan, T. M. Le, J. Mottahedeh, K. Ludwig, A. Eskin, Y. Qin, R. Levy, J. J. Breunig, F. Pajonk, T. G. Graeber, C. G. Radu, H. Christofk, R. M. Prins, A. Lai, L. M. Liao, G. Coppola, and H. I. Kornblum. "Metabolic Characterization of Isocitrate Dehydrogenase (Idh) Mutant and Idh Wildtype Gliomaspheres Uncovers Cell Type-Specific Vulnerabilities." *Cancer Metab* 6 (2018): 4.

127. Han, Xuetao, Huandi Zhou, Wei Sun, Liubing Hou, Yanqiang Wang, Hong Wang, Zhongqiang Lv, and Xiaoying Xue. "Idh1r132h Mutation Increases Radiotherapy Efficacy and a 4-Gene Radiotherapy-Related Signature of Who Grade 4 Gliomas." *Scientific Reports* 13, no. 1 (2023): 19659.
128. Kessler, J., A. Güttler, H. Wichmann, S. Rot, M. Kappler, M. Bache, and D. Vordermark. "Idh1(R132h) Mutation Causes a Less Aggressive Phenotype and Radiosensitizes Human Malignant Glioma Cells Independent of the Oxygenation Status." *Radiother Oncol* 116, no. 3 (2015): 381-7.
129. Cohen, A. L., S. L. Holmen, and H. Colman. "Idh1 and Idh2 Mutations in Gliomas." *Curr Neurol Neurosci Rep* 13, no. 5 (2013): 345.
130. Jiao, Y., P. J. Killela, Z. J. Reitman, A. B. Rasheed, C. M. Heaphy, R. F. de Wilde, F. J. Rodriguez, S. Rosemberg, S. M. Oba-Shinjo, S. K. Nagahashi Marie, C. Bettegowda, N. Agrawal, E. Lipp, C. Pirozzi, G. Lopez, Y. He, H. Friedman, A. H. Friedman, G. J. Riggins, M. Holdhoff, P. Burger, R. McLendon, D. D. Bigner, B. Vogelstein, A. K. Meeker, K. W. Kinzler, N. Papadopoulos, L. A. Diaz, and H. Yan. "Frequent Atrx, Cic, Fubp1 and Idh1 Mutations Refine the Classification of Malignant Gliomas." *Oncotarget* 3, no. 7 (2012): 709-22.
131. Núñez, F. J., F. M. Mendez, P. Kadiyala, M. S. Alghamri, M. G. Savelieff, M. B. Garcia-Fabiani, S. Haase, C. Koschmann, A. A. Calinescu, N. Kamran, M. Saxena, R. Patel, S. Carney, M. Z. Guo, M. Edwards, M. Ljungman, T. Qin, M. A. Sartor, R. Tagett, S. Venneti, J. Brosnan-Cashman, A. Meeker, V. Gorbunova, L. Zhao, D. M. Kremer, L. Zhang, C. A. Lyssiotis, L. Jones, C. J. Herting, J. L. Ross, D. Hambardzumyan, S. Hervey-Jumper, M. E. Figueroa, P. R. Lowenstein, and M. G. Castro. "Idh1-R132h Acts as a Tumor Suppressor in Glioma Via Epigenetic up-Regulation of the DNA Damage Response." *Sci Transl Med* 11, no. 479 (2019).
132. Cai, M., J. Zhao, Q. Ding, and J. Wei. "Oncometabolite 2-Hydroxyglutarate Regulates Anti-Tumor Immunity." *Heliyon* 10, no. 2 (2024): e24454.
133. Patel, S. H., A. G. Bansal, E. B. Young, P. P. Batchala, J. T. Patrie, M. B. Lopes, R. Jain, C. E. Fadul, and D. Schiff. "Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype." *AJNR Am J Neuroradiol* 40, no. 7 (2019): 1149-55.
134. Gill, B. J., D. J. Pisapia, H. R. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, J. S. Sims, M. Banu, A. Dovas, A. F. Teich, S. A. Sheth, G. M. McKhann, M. B. Sisti, J. N. Bruce, P. A. Sims, and P. Canoll. "Mri-Localized Biopsies Reveal Subtype-Specific Differences in Molecular and Cellular Composition at the Margins of Glioblastoma." *Proc Natl Acad Sci U S A* 111, no. 34 (2014): 12550-5.
135. Sottoriva, A., I. Spiteri, S. G. Piccirillo, A. Touloumis, V. P. Collins, J. C. Marioni, C. Curtis, C. Watts, and S. Tavaré. "Intratumor Heterogeneity in Human Glioblastoma Reflects Cancer Evolutionary Dynamics." *Proc Natl Acad Sci U S A* 110, no. 10 (2013): 4009-14.
136. Blanco-Carmona, E., A. Narayanan, I. Hernandez, J. C. Nieto, M. Elosua-Bayes, X. Sun, C. Schmidt, N. Pamir, K. Özduman, C. Herold-Mende, F. Pagani, M. Cominelli, J. Taranda, W. Wick, A. von Deimling, P. L. Poliani, M. Rehli, M. Schlesner, H. Heyn, and Ş Turcan. "Tumor Heterogeneity and Tumor-Microglia Interactions in Primary and Recurrent Idh1-Mutant Gliomas." *Cell Rep Med* 4, no. 11 (2023): 101249.
137. Pirozzi, Christopher J., and Hai Yan. "The Implications of Idh Mutations for Cancer Development and Therapy." *Nature Reviews Clinical Oncology* 18, no. 10 (2021): 645-61.
138. Śledzińska, Paulina, Marek Bebyn, Ewelina Szczerba, Jacek Furtak, Maciej Harat, Natalia Olszewska, Katarzyna Kamińska, Janusz Kowalewski, and Marzena A. Lewandowska. "Glioma 2021 Who Classification: The Superiority of Ngs over Ihc in Routine Diagnostics." *Molecular Diagnosis & Therapy* 26, no. 6 (2022): 699-713.
139. Vij, M., R. T. Yokoda, O. Rashidipour, I. Tran, V. Vasudevaraja, M. Snuderl, R. L. Yong, W. S. Cobb, M. Umphlett, J. M. Walker, N. M. Tsankova, and T. E. Richardson. "The Prognostic Impact of Subclonal Idh1 Mutation in Grade 2-4 Astrocytomas." *Neurooncol Adv* 5, no. 1 (2023): vdad069.
140. Singh, Rajesh R. "Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications." *The Journal of Molecular Diagnostics* 22, no. 8 (2020): 994-1007.
141. Pei, X. M., M. H. Y. Yeung, A. N. N. Wong, H. F. Tsang, A. C. S. Yu, A. K. Y. Yim, and S. C. C. Wong. "Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases." *Cells* 12, no. 3 (2023).
142. Qin, D. "Next-Generation Sequencing and Its Clinical Application." *Cancer Biol Med* 16, no. 1 (2019): 4-10.
143. Nikiforova, Marina N., Abigail I. Wald, Melissa A. Melan, Somak Roy, Shan Zhong, Ronald L. Hamilton, Frank S. Lieberman, Jan Drappatz, Nduka M. Amankulor, Ian F. Pollack, Yuri E. Nikiforov, and Craig Horbinski. "Targeted Next-Generation Sequencing Panel (Glioseq) Provides Comprehensive Genetic Profiling of Central Nervous System Tumors." *Neuro-Oncology* 18, no. 3 (2015): 379-87.
144. Zacher, Angela, Kerstin Kaulich, Stefanie Stepanow, Marietta Wolter, Karl Köhrer, Jörg Felsberg, Bastian Malzkorn, and Guido Reifenberger. "Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel." *Brain Pathology* 27, no. 2 (2017): 146-59.
145. Higa, Nayuta, Toshiaki Akahane, Seiya Yokoyama, Hajime Yonezawa, Hiroyuki Uchida, Tomoko Takajo, Mari Kirishima, Taiji Hamada, Kei Matsuo, Shingo Fujio, Tomoko Hanada, Hiroshi Hosoyama, Masanori

- Yonenaga, Akihisa Sakamoto, Tsubasa Hiraki, Akihide Tanimoto, and Koji Yoshimoto. "A Tailored Next-Generation Sequencing Panel Identified Distinct Subtypes of Wildtype Idh and Tert Promoter Glioblastomas." *Cancer Science* 111, no. 10 (2020): 3902-11.
146. Guarnaccia, Maria, Laura Guarnaccia, Valentina La Cognata, Stefania Elena Navone, Rolando Campanella, Antonella Ampollini, Marco Locatelli, Monica Miozzo, Giovanni Marfia, and Sebastiano Cavallaro. "A Targeted Next-Generation Sequencing Panel to Genotype Gliomas." *Life* 12, no. 7 (2022): 956.
 147. Tirrò, Elena, Michele Massimino, Giuseppe Broggi, Chiara Romano, Simone Minasi, Francesca Gianni, Manila Antonelli, Gianmarco Motta, Francesco Certo, Roberto Altieri, Livia Manzella, Rosario Caltabiano, Giuseppe Maria Vincenzo Barbagallo, Francesca Romana Buttarelli, Gaetano Magro, Felice Giangaspero, and Paolo Vigneri. "A Custom DNA-Based Ngs Panel for the Molecular Characterization of Patients with Diffuse Gliomas: Diagnostic and Therapeutic Applications." *Frontiers in Oncology* 12 (2022).
 148. de Biase, Dario, Giorgia Acquaviva, Michela Visani, Gianluca Marucci, Antonio De Leo, Thais Maloberti, Viviana Sanza, Enrico Di Oto, Enrico Franceschi, Antonella Mura, Moira Ragazzi, Silvia Serra, Elisabetta Froio, Alessandra Bisagni, Alba A. Brandes, Annalisa Pession, and Giovanni Tallini. "Next-Generation Sequencing Panel for 1p/19q Codeletion and Idh1-Idh2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion By fish." *The Journal of Molecular Diagnostics* 23, no. 9 (2021): 1185-94.
 149. Lorenz, Julia, Tanja Rothhammer-Hampl, Saida Zoubaa, Elisabeth Bumès, Tobias Pukrop, Oliver Kölbl, Selim Corbacioglu, Nils O. Schmidt, Martin Proescholdt, Peter Hau, and Markus J. Riemenschneider. "A Comprehensive DNA Panel Next Generation Sequencing Approach Supporting Diagnostics and Therapy Prediction in Neurooncology." *Acta Neuropathologica Communications* 8, no. 1 (2020): 124.
 150. Yaltirik, Cumhur Kaan, Seda Gulec Yilmaz, Selcuk Ozdogan, Ezel Yaltirik Bilgin, Zerrin Barut, Ugur Ture, and Turgay Isbir. "Determination of ≪Em≫Idh1, Idh2, Mgmt, Tert≪/Em≫ and ≪Em≫Atrx≪/Em≫ Gene Mutations in Glial Tumors." *In Vivo* 36, no. 4 (2022): 1694.
 151. Wongsurawat, Thidathip, Piroon Jenjaroenpun, Panatna Anekwiang, Tantip Arigul, Wichayapat Thongrattana, Azemat Jamshidi-Parsian, Gunnar Boysen, Prapat Suriyaphol, Bhoom Suktitipat, Prajak Srirabheebhat, Pornsuk Cheunsuchon, Jantima Tanboon, Intawat Nookaew, and Sith Sathornsumtee. "Exploiting Nanopore Sequencing for Characterization and Grading of Idh-Mutant Gliomas." *Brain Pathology* 34, no. 1 (2024): e13203.
 152. Mimosa, Mashiat L., Wafa Al-ameri, Jared T. Simpson, Michael Nakhla, Karel Boissinot, David G. Munoz, Sunit Das, Harriet Feilotter, Ramzi Fattouh, and Rola M. Saleeb. "A Novel Approach to Detect Idh Point Mutations in Gliomas Using Nanopore Sequencing: Test Validation for the Clinical Laboratory." *The Journal of Molecular Diagnostics* 25, no. 3 (2023): 133-42.
 153. Patel, Areeba, Helin Dogan, Alexander Payne, Elena Krause, Philipp Sievers, Natalie Schoebe, Daniel Schrimpf, Christina Blume, Damian Stichel, Nadine Holmes, Philipp Euskirchen, Jürgen Hench, Stephan Frank, Violaine Rosenstiel-Goidts, Miriam Ratliff, Nima Etmianan, Andreas Unterberg, Christoph Dieterich, Christel Herold-Mende, Stefan M. Pfister, Wolfgang Wick, Matthew Loose, Andreas von Deimling, Martin Sill, David T. W. Jones, Matthias Schlesner, and Felix Sahm. "Rapid-Cns2: Rapid Comprehensive Adaptive Nanopore-Sequencing of Cns Tumors, a Proof-of-Concept Study." *Acta Neuropathologica* 143, no. 5 (2022): 609-12.
 154. Shirai, Yukina, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Rina Kitada, Takafumi Koyama, Fumiyuki Takahashi, Kazuhisa Takahashi, Koichi Ichimura, Akihiko Yoshida, Hirokazu Sugino, Hiroyuki Mano, Yoshitaka Narita, Masamichi Takahashi, and Shinji Kohsaka. "The Development of a Custom Rna-Sequencing Panel for the Identification of Predictive and Diagnostic Biomarkers in Glioma." *Journal of Neuro-Oncology* 167, no. 1 (2024): 75-88.
 155. Byron, Sara A., Kendall R. Van Keuren-Jensen, David M. Engelthaler, John D. Carpten, and David W. Craig. "Translating Rna Sequencing into Clinical Diagnostics: Opportunities and Challenges." *Nature Reviews Genetics* 17, no. 5 (2016): 257-71.
 156. Couturier, Charles P., Shamini Ayyadhury, Phuong U. Le, Javad Nadaf, Jean Monlong, Gabriele Riva, Redouane Allache, Salma Baig, Xiaohua Yan, Mathieu Bourgey, Changseok Lee, Yu Chang David Wang, V. Wee Yong, Marie-Christine Guiot, Hamed Najafabadi, Bratislav Misic, Jack Antel, Guillaume Bourque, Jiannis Ragoussis, and Kevin Petrecca. "Single-Cell Rna-Seq Reveals That Glioblastoma Recapitulates a Normal Neurodevelopmental Hierarchy." *Nature Communications* 11, no. 1 (2020): 3406.
 157. Piwecka, Monika, Nikolaus Rajewsky, and Agnieszka Rybak-Wolf. "Single-Cell and Spatial Transcriptomics: Deciphering Brain Complexity in Health and Disease." *Nature Reviews Neurology* 19, no. 6 (2023): 346-62.
 158. Venteicher, Andrew S., Itay Tirosh, Christine Hebert, Keren Yizhak, Cyril Neftel, Mariella G. Filbin, Volker Hovestadt, Leah E. Escalante, McKenzie L. Shaw, Christopher Rodman, Shawn M. Gillespie, Danielle Dionne, Christina C. Luo, Hiranmayi Ravichandran, Ravindra Mylvaganam, Christopher Mount, Maristela L. Onozato, Brian V. Nahed, Hiroaki Wakimoto, William T. Curry, A. John Iafrate, Miguel N. Rivera, Matthew P. Frosch, Todd R. Golub, Priscilla K. Brastianos, Gad Getz, Anoop P. Patel, Michelle Monje, Daniel P. Cahill, Orit Rozenblatt-Rosen, David N. Louis, Bradley E. Bernstein, Aviv Regev, and Mario L.

- Suvà. "Decoupling Genetics, Lineages, and Microenvironment in Idh-Mutant Gliomas by Single-Cell Rna-Seq." *Science* 355, no. 6332 (2017): eaai8478.
159. Martínez-Ricarte, F., R. Mayor, E. Martínez-Sáez, C. Rubio-Pérez, E. Pineda, E. Cordero, M. Cicuéndez, M. A. Poca, N. López-Bigas, Y. Cajal S. Ramon, M. Vieito, J. Carles, J. Taberner, A. Vivancos, S. Gallego, F. Graus, J. Sahuquillo, and J. Seoane. "Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid." *Clin Cancer Res* 24, no. 12 (2018): 2812-19.
 160. Mair, Richard, and Florent Mouliere. "Cell-Free DNA Technologies for the Analysis of Brain Cancer." *British Journal of Cancer* 126, no. 3 (2022): 371-78.
 161. De Mattos-Arruda, L., R. Mayor, C. K. Y. Ng, B. Weigelt, F. Martínez-Ricarte, D. Torrejon, M. Oliveira, A. Arias, C. Raventos, J. Tang, E. Guerini-Rocco, E. Martínez-Sáez, S. Lois, O. Marín, X. de la Cruz, S. Piscuoglio, R. Towers, A. Vivancos, V. Peg, S. Ramon y Cajal, J. Carles, J. Rodon, M. González-Cao, J. Taberner, E. Felip, J. Sahuquillo, M. F. Berger, J. Cortes, J. S. Reis-Filho, and J. Seoane. "Cerebrospinal Fluid-Derived Circulating Tumour DNA Better Represents the Genomic Alterations of Brain Tumours Than Plasma." *Nat Commun* 6 (2015): 8839.
 162. Wongsurawat, Thidathip, Piroon Jenjaroenpun, Annick De Loose, Duah Alkam, David W. Ussery, Intawat Nookaew, Yuet-Kin Leung, Shuk-Mei Ho, John D. Day, and Analiz Rodriguez. "A Novel Cas9-Targeted Long-Read Assay for Simultaneous Detection of Idh1/2 Mutations and Clinically Relevant Mgmt Methylation in Fresh Biopsies of Diffuse Glioma." *Acta Neuropathologica Communications* 8, no. 1 (2020): 87.
 163. Feng, Zhebin, Dongsheng Kong, Wei Jin, Kunyu He, Junyan Zhao, Bin Liu, Hanyun Xu, Xir'guang Yu, and Shiyu Feng. "Rapid Detection of Isocitrate Dehydrogenase 1 Mutation Status in Glioma Based on Crispr-Cas12a." *Scientific Reports* 13, no. 1 (2023): 5748.
 164. Yu, Donghu, Qisheng Zhong, Yilei Xiao, Zhebin Feng, Feng Tang, Shiyu Feng, Yuxiang Cai, Yutong Gao, Tian Lan, Mingjun Li, Fuhua Yu, Zefen Wang, Xu Gao, and Zhiqiang Li. "Combination of Mri-Based Prediction and Crispr/Cas12a-Based Detection for Idh Genotyping in Glioma." *npj Precision Oncology* 8, no. 1 (2024): 140.
 165. Wang, X., M. Zhong, Y. Liu, P. Ma, L. Dang, Q. Meng, W. Wan, X. Ma, J. Liu, G. Yang, Z. Yang, X. Huang, and M. Liu. "Rapid and Sensitive Detection of Covid-19 Using Crispr/Cas12a-Based Detection with Naked Eye Readout, Crispr/Cas12a-Ner." *Sci Bull (Beijing)* 65, no. 17 (2020): 1436-39.
 166. Tsou, J. H., Q. Leng, and F. Jiang. "A Crispr Test for Rapidly and Sensitive Detecting Circulating Egfr Mutations." *Diagnostics (Basel)* 10, no. 2 (2020).
 167. Murugan, K., A. S. Seetharam, A. J. Severin, and D. G. Sashital. "Crispr-Cas12a Has Widespread Off-Target and Dsdna-Nicking Effects." *J Biol Chem* 295, no. 17 (2020): 5538-53.
 168. Zhou, Jin, Peng Chen, Hongjian Wang, Huan Liu, Yongzheng Li, Youpeng Zhang, Yankang Wu, Chonil Paek, Zaiqiao Sun, Jun Lei, and Lei Yin. "Cas12a Variants Designed for Lower Genome-Wide Off-Target Effect through Stringent Pam Recognition." *Molecular Therapy* 30, no. 1 (2022): 244-55.
 169. Kloosterhof, Nanne K., Johan J. de Rooij, Max Kros, Paul H. C. Eilers, Peter A. E. Sillevius Smitt, Martin J. van den Bent, and Pim J. French. "Molecular Subtypes of Glioma Identified by Genome-Wide Methylation Profiling." *Genes, Chromosomes and Cancer* 52, no. 7 (2013): 665-74.
 170. Capper, D., D. Stichel, F. Sahm, D. T. W. Jones, D. Schrimpf, M. Sill, S. Schmid, V. Hovestadt, D. E. Reuss, C. Koelsche, A. Reinhardt, A. K. Wefers, K. Huang, P. Sievers, A. Ebrahimi, A. Schöler, D. Teichmann, A. Koch, D. Hänggi, A. Unterberg, M. Platten, W. Wick, O. Witt, T. Milde, A. Korshunov, S. M. Pfister, and A. von Deimling. "Practical Implementation of DNA Methylation and Copy-Number-Based Cns Tumor Diagnostics: The Heidelberg Experience." *Acta Neuropathol* 136, no. 2 (2018): 181-210.
 171. Bai, H., A. S. Harmanci, E. Z. Erson-Omay, J. Li, S. Coskun, M. Simon, B. Krischek, K. Ozduman, S. B. Omay, E. A. Sorensen, S. Turcan, M. Bakirciglu, G. Carrion-Grant, P. B. Murray, V. E. Clark, A. G. Ercan-Sencicek, J. Knight, L. Sencar, S. Altinok, L. D. Kaulen, B. Gulez, M. Timmer, J. Schramm, K. Mishra-Gorur, O. Henegariu, J. Moliterno, A. Louvi, T. A. Chan, S. L. Tannheimer, M. N. Pamir, A. O. Vortmeyer, K. Bilguvar, K. Yasuno, and M. Gunel. "Integrated Genomic Characterization of Idh1-Mutant Glioma Malignant Progression." *Nat Genet* 48, no. 1 (2016): 59-66.
 172. Schenkel, Laila C., Joseph Mathew, Hal Hirte, John Provias, Guillaume Paré, Michael Chong, Daria Grafodatskaya, and Elizabeth McCready. "Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish Idh1/Idh2 Mutant and Wild-Type Tumors." *Genes* 13, no. 11 (2022): 2075.
 173. Euskirchen, P., F. Bielle, K. Labreche, W. P. Kloosterman, S. Rosenberg, M. Daniau, C. Schmitt, J. Masliah-Planchon, F. Bourdeaut, C. Dehais, Y. Marie, J. Y. Delattre, and A. Idhailh. "Same-Day Genomic and Epigenomic Diagnosis of Brain Tumors Using Real-Time Nanopore Sequencing." *Acta Neuropathol* 134, no. 5 (2017): 691-703.
 174. Willscher, Edith, Lydia Hopp, Markus Kreuz, Maria Schmidt, Siras Hakobyan, Arsen Arakelyan, Bettina Hentschel, David T. W. Jones, Stefan M. Pfister, Markus Loeffler, Henry Loeffler-Wirth, and Hans Binder. "High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas." *Cancers* 13, no. 13 (2021): 3198.

175. Wenger, A., and H. Carén. "Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations." *Cancers (Basel)* 14, no. 22 (2022).
176. Djirackor, Luna, Skarphedinn Halldorsson, Pitt Niehusmann, Henning Leske, David Capper, Luis P Kuschel, Jens Pahnke, Bernt J Due-Tønnessen, Iver A Langmoen, Cecilie J Sandberg, Philipp Euskirchen, and Einar O Vik-Mo. "Intraoperative DNA Methylation Classification of Brain Tumors Impacts Neurosurgical Strategy." *Neuro-Oncology Advances* 3, no. 1 (2021).
177. Zhang, Junjie, Shuilian Xie, Jingxiang Xu, Hui Liu, and Shaogui Wan. "Cancer Biomarkers Discovery of Methylation Modification with Direct High-Throughput Nanopore Sequencing." *Frontiers in Genetics* 12 (2021).
178. Beiko, J., D. Suki, K. R. Hess, B. D. Fox, V. Cheung, M. Cabral, N. Shonka, M. R. Gilbert, R. Sawaya, S. S. Prabhu, J. Weinberg, F. F. Lang, K. D. Aldape, E. P. Sulman, G. Rao, I. E. McCutcheon, and D. P. Cahill. "Idh1 Mutant Malignant Astrocytomas Are More Amenable to Surgical Resection and Have a Survival Benefit Associated with Maximal Surgical Resection." *Neuro Oncol* 16, no. 1 (2014): 81-91.
179. Cahill, D. P. "Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era." *Neurosurg Clin N Am* 32, no. 1 (2021): 23-29.
180. Jakola, A. S., L. K. Pedersen, A. J. Skjulsvik, K. Myrmed, K. Sjavik, and O. Solheim. "The Impact of Resection in Idh-Mutant WHO Grade 2 Gliomas: A Retrospective Population-Based Parallel Cohort Study." *J Neurosurg* (2022): 1-8.
181. Wolter, Marietta, Jörg Felsberg, Bastian Malzkorn, Kerstin Kaulich, and Guido Reifenberger. "Droplet Digital Pcr-Based Analyses for Robust, Rapid, and Sensitive Molecular Diagnostics of Gliomas." *Acta Neuropathologica Communications* 10, no. 1 (2022): 42.
182. Wang, J., Y. Y. Zhao, J. F. Li, C. C. Guo, F. R. Chen, H. K. Su, H. F. Zhao, Y. K. Long, J. Y. Shao, Ss To, and Z. P. Chen. "Idh1 Mutation Detection by Droplet Digital Pcr in Glioma." *Oncotarget* 6, no. 37 (2015): 39651-60.
183. Perizzolo, M., B. Winkfein, S. Hui, W. Krulicki, J. A. Chan, and D. J. Demetrick. "Idh Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex Pcr and Single-Base Extension." *Brain Pathol* 22, no. 5 (2012): 619-24.
184. Chen, Walter W., Leonora Balaj, Linda M. Liau, Michael L. Samuels, Steve K. Kotsopoulos, Casey A. Maguire, Lori LoGuidice, Horacio Soto, Matthew Garrett, Lin Dan Zhu, Sarada Sivaraman, Clark Chen, Eric T. Wong, Bob S. Carter, Fred H. Hochberg, Xandra O. Breakefield, and Johan Skog. "Beaming and Droplet Digital Pcr Analysis of Mutant Idh1 Mrna in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles." *Molecular Therapy - Nucleic Acids* 2 (2013).
185. Yang, Jin, Nana Zhang, Jun Lv, Ping Zhu, Xing Pan, Jiaqingzi Hu, Wenfeng Wu, Shan Li, and Hongtao Li. "Comparing the Performance of Conventional Pcr, Rtg-Pcr, and Droplet Digital Pcr Assays in Detection of Shigella." *Molecular and Cellular Probes* 51 (2020): 101531.
186. Orzan, Francesca, Francesca De Bacco, Elisabetta Lazzarini, Giovanni Crisafulli, Alessandra Gasparini, Angelo Dipasquale, Ludovic Barault, Marco Macagno, Pasquale Persico, Federico Pessina, Beatrice Bono, Laura Giordano, Pietro Zeppa, Antonio Melcarne, Paola Cassoni, Diego Garbossa, Armando Santoro, Paolo M. Comoglio, Stefano Indraccolo, Matteo Simonelli, and Carla Boccaccio. "Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation." *Clinical Cancer Research* 29, no. 7 (2023): 1252-66.
187. Crucitta, Stefania, Francesco Pasqualetti, Alessandra Gonnelli, Martina Ruglioni, Giovanna Irene Luculli, Martina Cantarella, Valerio Ortenzi, Cristian Scatena, Fabiola Paiar, Antonio Giuseppe Naccarato, Romano Danesi, and Marzia Del Re. "Idh1 Mutation Is Detectable in Plasma Cell-Free DNA and Is Associated with Survival Outcome in Glioma Patients." *BMC Cancer* 24, no. 1 (2024): 31.
188. Jones, Jordan J, Hong Nguyen, Stephen Q Wong, James Whittle, Josie Iaria, Stanley Stylli, James Towner, Thomas Pieters, Frank Gaillard, Andrew H Kaye, Katharine J Drummond, and Andrew P Morokoff. "Plasma Ctdna Liquid Biopsy of Idh1, Tertp, and Egfrviii Mutations in Glioma." *Neuro-Oncology Advances* 6, no. 1 (2024).
189. Husain, A., S. Mishra, M. H. Siddiqui, and N. Husain. "Detection of Idh1 Mutation in Cfdna and Tissue of Adult Diffuse Glioma with Allele-Specific Qpcr." *Asian Pac J Cancer Prev* 24, no. 3 (2023): 961-68.
190. Solomon, James P., Carlos Munoz-Zuluaga, Cheyanne Slocum, Alicia Dillard, Lin Cong, Jiajing Wang, Neal Lindeman, Michael Kluk, Benjamin Liechty, David Pisapia, Hanna Rennert, and Priya D. Velu. "Evaluation of the Rapid Idylla Idh1-2 Mutation Assay in Ffpe Glioma Samples." *Diagnostic Pathology* 19, no. 1 (2024): 70.
191. Choate, K. A., E. J. Raack, V. F. Line, M. J. Jennings, R. J. Belton, Jr., R. J. Winn, and P. B. Mann. "Rapid Extraction-Free Detection of the R132h Isocitrate Dehydrogenase Mutation in Glioma Using Colorimetric Peptide Nucleic Acid-Loop Mediated Isothermal Amplification (Cpna-Lamp)." *PLoS One* 18, no. 9 (2023): e0291666.

192. Choate, Kristian A, Edward J Raack, Paul B Mann, Evan A Jones, Robert J Winn, and Matthew J Jennings. "Rapid Idh1-R132 Genotyping Panel Utilizing Locked Nucleic Acid Loop-Mediated Isothermal Amplification (Lna-Lamp)." *Biology Methods and Protocols* (2024).
193. Yoshida, Akihiko, Kaishi Satomi, Makoto Ohno, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Nobuyoshi Hiraoka, Yoshitaka Narita, and Koichi Ichimura. "Frequent False-Negative Immunohistochemical Staining with Idh1 (R132h)-Specific H09 Antibody on Frozen Section Control Slides: A Potential Pitfall in Glioma Diagnosis." *Histopathology* 74, no. 2 (2019): 350-54.
194. Capper, D., H. Zentgraf, J. Balss, C. Hartmann, and A. von Deimling. "Monoclonal Antibody Specific for Idh1 R132h Mutation." *Acta Neuropathol* 118, no. 5 (2009): 599-601.
195. Kato, Y., G. Jin, C. T. Kuan, R. E. McLendon, H. Yan, and D. D. Bigner. "A Monoclonal Antibody Imab-1 Specifically Recognizes Idh1r132h, the Most Common Glioma-Derived Mutation." *Biochem Biophys Res Commun* 390, no. 3 (2009): 547-51.
196. Kato, Y. "Specific Monoclonal Antibodies against Idh1/2 Mutations as Diagnostic Tools for Gliomas." *Brain Tumor Pathol* 32, no. 1 (2015): 3-11.
197. Copaciu, R., J. Rashidian, J. Lloyd, A. Yahyabeik, J. McClure, K. Cummings, and Q. Su. "Characterization of an Idh1 R132h Rabbit Monoclonal Antibody, Mrq-67, and Its Applications in the Identification of Diffuse Gliomas." *Antibodies (Basel)* 12, no. 1 (2023).
198. Rashidian, J., R. Copaciu, Q. Su, B. Merritt, C. Johnson, A. Yahyabeik, E. French, and K. Cummings. "Generation and Performance of R132h Mutant Idh1 Rabbit Monoclonal Antibody." *Antibodies (Basel)* 6, no. 4 (2017).
199. Lu, V. M., and K. L. McDonald. "Isocitrate Dehydrogenase 1 Mutation Subtypes at Site 132 and Their Translational Potential in Glioma." *CNS Oncol* 7, no. 1 (2018): 41-50.
200. Agarwal, S., M. C. Sharma, P. Jha, P. Pathak, V. Suri, C. Sarkar, K. Chosdol, A. Suri, S. S. Kale, A. K. Mahapatra, and P. Jha. "Comparative Study of Idh1 Mutations in Gliomas by Immunohistochemistry and DNA Sequencing." *Neuro Oncol* 15, no. 6 (2013): 718-26.
201. Zhang, Sarah, and Christopher William. "Educational Case: Histologic and Molecular Features of Diffuse Gliomas." *Academic Pathology* 7 (2020): 2374289520914021.
202. Nakagaki, Riku, Shyam Sundar Debsarkar, Hiroharu Kawanaka, Bruce J. Aronow, and V. B. Surya Prasath. "Deep Learning-Based Idh1 Gene Mutation Prediction Using Histopathological Imaging and Clinical Data." *Computers in Biology and Medicine* 179 (2024): 108902.
203. Liu, Sidong, Zubair Shah, Aydin Sav, Carlo Russo, Shlomo Berkovsky, Yi Qian, Enrico Coiera, and Antonio Di Ieva. "Isocitrate Dehydrogenase (Idh) Status Prediction in Histopathology Images of Gliomas Using Deep Learning." *Scientific Reports* 10, no. 1 (2020): 7733.
204. Liechty, Benjamin, Zhuoran Xu, Zhilu Zhang, Cheyanne Slocum, Cagla D. Bahadir, Mert R. Sabuncu, and David J. Pisapia. "Machine Learning Can Aid in Prediction of Idh Mutation from H&E-Stained Histology Slides in Infiltrating Gliomas." *Scientific Reports* 12, no. 1 (2022): 22623.
205. Chundururu, Pranathi, Joanna J Phillips, and Annette M Molinaro. "Prognostic Risk Stratification of Gliomas Using Deep Learning in Digital Pathology Images." *Neuro-Oncology Advances* 4, no. 1 (2022).
206. Cui, Danni, Yingying Liu, Gang Liu, and Lei Liu. "A Multiple-Instance Learning-Based Convolutional Neural Network Model to Detect the Idh1 Mutation in the Histopathology Images of Glioma Tissues." *Journal of computational biology* 27, no. 8 (2020): 1264-72.
207. Arita, H., Y. Narita, A. Yoshida, N. Hashimoto, T. Yoshimine, and K. Ichimura. "Idh1/2 Mutation Detection in Gliomas." *Brain Tumor Pathol* 32, no. 2 (2015): 79-89.
208. Yang, Jun, Hanwen Zhu, Tianlong Zhang, and Jianping Ding. "Structure, Substrate Specificity, and Catalytic Mechanism of Human D-2-Hgdh and Insights into Pathogenicity of Disease-Associated Mutations." *Cell Discovery* 7, no. 1 (2021): 3.
209. de Goede, Kyra E., Karl J. Harber, Friederike S. Gorki, Sanne G. S. Verberk, Laszlo A. Groh, Eelco D. Keuning, Eduard A. Struys, Michel van Weeghel, Arvand Haschemi, Menno P. J. de Winther, Xanthe A. M. H. van Dierendonck, and Jan Van den Bossche. "D-2-Hydroxyglutarate Is an Anti-Inflammatory Immunometabolite That Accumulates in Macrophages after Tlr4 Activation." *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1868, no. 9 (2022): 166427.
210. ACHOURI, Younes, Gaëtane NOËL, Didier VERTOMMEN, Mark H. RIDER, Maria VEIGA-DA-CUNHA, and Emile van SCHAFTINGEN. "Identification of a Dehydrogenase Acting on D-2-Hydroxyglutarate." *Biochemical Journal* 381, no. 1 (2004): 35-42.
211. Struys, Eduard A. "D-2-Hydroxyglutaric Aciduria: Unravelling the Biochemical Pathway and the Genetic Defect." *Journal of Inherited Metabolic Disease* 29, no. 1 (2006): 21-29.
212. Tuna, G., N. E. Dal-Bekar, A. Akay, M. Rükşen, S. İşlekel, and G. H. İşlekel. "Minimally Invasive Detection of Idh1 Mutation with Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas." *J Neuropathol Exp Neurol* 81, no. 7 (2022): 502-10.
213. Kalinina, J., J. Ahn, N. S. Devi, L. Wang, Y. Li, J. J. Olson, M. Glantz, T. Smith, E. L. Kim, A. Giese, R. L. Jensen, C. C. Chen, B. S. Carter, H. Mao, M. He, and E. G. Van Meir. "Selective Detection of the D-

- Enantiomer of 2-Hydroxyglutarate in the Csf of Glioma Patients with Mutated Isocitrate Dehydrogenase." *Clin Cancer Res* 22, no. 24 (2016): 6256-65.
214. Fujita, Y., L. Nunez-Rubiano, A. Dono, A. Bellman, M. Shah, J. C. Rodriguez, V. Putluri, A. H. M. Kamal, N. Putluri, R. F. Riascos, J. J. Zhu, Y. Esquenazi, and L. Y. Ballester. "Idh1 P.R132h Ctdna and D-2-Hydroxyglutarate as Csf Biomarkers in Patients with Idh-Mutant Gliomas." *J Neurooncol* 159, no. 2 (2022): 261-70.
215. Lee, C. L., G. M. O'Kane, W. P. Mason, W. J. Zhang, P. Spiliopoulou, A. R. Hansen, R. C. Grant, J. J. Knox, T. L. Stockley, G. Zadeh, and E. X. Chen. "Circulating Oncometabolite 2-Hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (Idh1/2) Mutant Cholangiocarcinoma." *Mol Cancer Ther* 23, no. 3 (2024): 394-99.
216. Delahousse, Julia, Loic Verlingue, Sophie Broutin, Clémence Legoupil, Mehdi Touat, Ludovic Doucet, Samy Ammari, Ludovic Lacroix, Michel Ducreux, Jean-Yves Scoazec, David Malka, Angelo Paci, and Antoine Hollebecque. "Circulating Oncometabolite D-2-Hydroxyglutarate Enantiomer Is a Surrogate Marker of Isocitrate Dehydrogenase-Mutated Intrahepatic Cholangiocarcinomas." *European Journal of Cancer* 90 (2018): 83-91.
217. Strain, Shinji K., Morris D. Groves, and Mark R. Emmett. "Enantioseparation and Detection of (R)-2-Hydroxyglutarate and (S)-2-Hydroxyglutarate by Chiral Gas Chromatography-Triple Quadrupole Mass Spectrometry." In *Metabolomics*, edited by Paul L. Wood, 89-100. New York, NY: Springer US, 2021.
218. Voelxen, N. F., S. Walenta, M. Proescholdt, K. Dettmer, S. Pusch, and W. Mueller-Klieser. "Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique." *Front Oncol* 6 (2016): 46.
219. Fernandez-Galan, E., N. Massana, M. Parra-Robert, S. Hidalgo, G. Casals, J. Esteve, and W. Jimenez. "Validation of a Routine Gas Chromatography Mass Spectrometry Method for 2-Hydroxyglutarate Quantification in Human Serum as a Screening Tool for Detection of Idh Mutations." *J Chromatogr B Analyt Technol Biomed Life Sci* 1083 (2018): 28-34.
220. Choi, C., S. K. Ganji, R. J. DeBerardinis, K. J. Hatanpaa, D. Rakheja, Z. Kovacs, X. L. Yang, T. Mashimo, J. M. Raisanen, I. Marin-Valencia, J. M. Pascual, C. J. Madden, B. E. Mickey, C. R. Malloy, R. M. Bachoo, and E. A. Maher. "2-Hydroxyglutarate Detection by Magnetic Resonance Spectroscopy in Idh-Mutated Patients with Gliomas." *Nat Med* 18, no. 4 (2012): 624-9.
221. Balss, Jörg, Stefan Pusch, Ann-Christin Beck, Christel Herold-Mende, Alwin Krämer, Christian Thiede, Wolfgang Buckel, Claus-Dieter Langhans, Jürgen G. Okun, and Andreas von Deimling. "Enzymatic Assay for Quantitative Analysis of (D)-2-Hydroxyglutarate." *Acta Neuropathologica* 124, no. 6 (2012): 883-91.
222. Xiao, Dan, Xianzhi Xu, Kaiyu Gao, Mengjiao Wang, Wen Zhang, Chuanjuan Lü, Xia Wang, Qian Wang, Ping Xu, Cuiqing Ma, and Chao Gao. "A Förster Resonance Energy Transfer-Based D-2-Hydroxyglutarate Biosensor." *Sensors and Actuators B: Chemical* 385 (2023): 133681.
223. Choate, Kristian Alissa, Wren W. L. Konickson, Matthew James Jennings, Paul Barrie Mann, Robert James Winn, David O. Kamson, and Evan P. S. Pratt. "A Genetically Encoded Fluorescent Sensor Enables Sensitive and Specific Detection of Idh Mutant Associated Oncometabolite D-2-Hydroxyglutarate." *bioRxiv* (2024): 2024.09.25.615072.
224. Fan, B., D. Dai, C. D. DiNardo, E. Stein, S. de Botton, E. C. Attar, H. Liu, G. Liu, I. Lemieux, S. V. Agresta, and H. Yang. "Clinical Pharmacokinetics and Pharmacodynamics of Ivosidenib in Patients with Advanced Hematologic Malignancies with an Idh1 Mutation." *Cancer Chemother Pharmacol* 85, no. 5 (2020): 959-68.
225. Fan, B., I. K. Mellinghoff, P. Y. Wen, M. A. Lowery, L. Goyal, W. D. Tap, S. S. Pandya, E. Manyak, L. Jiang, G. Liu, T. Nimkar, C. Gliser, M. Prah Judge, S. Agresta, H. Yang, and D. Dai. "Clinical Pharmacokinetics and Pharmacodynamics of Ivosidenib, an Oral, Targeted Inhibitor of Mutant Idh1, in Patients with Advanced Solid Tumors." *Invest New Drugs* 38, no. 2 (2020): 433-44.
226. Pusch, S., L. Schweizer, A. C. Beck, J. M. Lehmler, S. Weissert, J. Balss, A. K. Miller, and A. von Deimling. "D-2-Hydroxyglutarate Producing Neo-Enzymatic Activity Inversely Correlates with Frequency of the Type of Isocitrate Dehydrogenase 1 Mutations Found in Glioma." *Acta Neuropathol Commun* 2 (2014): 19.
227. Wang, Y. Y., K. Wang, S. W. Li, J. F. Wang, J. Ma, T. Jiang, and J. P. Dai. "Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with Idh1 Mutation." *AJNR Am J Neuroradiol* 36, no. 11 (2015): 2023-9.
228. Carrillo, J. A., A. Lai, P. L. Nghiemphu, H. J. Kim, H. S. Phillips, S. Kharbanda, P. Moftakhar, S. Lalaezari, W. Yong, B. M. Ellingson, T. F. Cloughesy, and W. B. Pope. "Relationship between Tumor Enhancement, Edema, Idh1 Mutational Status, Mgmt Promoter Methylation, and Survival in Glioblastoma." *AJNR Am J Neuroradiol* 33, no. 7 (2012): 1349-55.
229. Xing, Z., X. Yang, D. She, Y. Lin, Y. Zhang, and D. Cao. "Noninvasive Assessment of Idh Mutational Status in World Health Organization Grade Ii and Iii Astrocytomas Using Dwi and Dsc-Pwi Combined with Conventional Mr Imaging." *AJNR Am J Neuroradiol* 38, no. 6 (2017): 1138-44.
230. Li, Y., Q. Qin, Y. Zhang, and Y. Cao. "Noninvasive Determination of the Idh Status of Gliomas Using Mri and Mri-Based Radiomics: Impact on Diagnosis and Prognosis." *Curr Oncol* 29, no. 10 (2022): 6893-907.

231. Kates, R., D. Atkinson, and M. Brant-Zawadzki. "Fluid-Attenuated Inversion Recovery (Flair): Clinical Prospectus of Current and Future Applications." *Top Magn Reson Imaging* 8, no. 6 (1996): 389-96.
232. Patel, S. H., L. M. Poisson, D. J. Brat, Y. Zhou, L. Cooper, M. Snuderl, C. Thomas, A. M. Franceschi, B. Griffith, A. E. Flanders, J. G. Golfinos, A. S. Chi, and R. Jain. "T2-Flair Mismatch, an Imaging Biomarker for Idh and 1p/19q Status in Lower-Grade Gliomas: A Tcga/Tcia Project." *Clin Cancer Res* 23, no. 20 (2017): 6078-85.
233. Pinto, C., C. Noronha, R. Taipa, and C. Ramos. "T2-Flair Mismatch Sign: A Roadmap of Pearls and Pitfalls." *Br J Radiol* 95, no. 1129 (2022): 20210825.
234. Jain, R., D. R. Johnson, S. H. Patel, M. Castillo, M. Smits, M. J. van den Bent, A. S. Chi, and D. P. Cahill. "'Real World' Use of a Highly Reliable Imaging Sign: 'T2-Flair Mismatch' for Identification of Idh Mutant Astrocytomas." *Neuro Oncol* 22, no. 7 (2020): 936-43.
235. Shoaib, Y., K. Nayil, R. Makhdoomi, A. Asma, A. Ramzan, F. Shaheen, and A. Wani. "Role of Diffusion and Perfusion Magnetic Resonance Imaging in Predicting the Histopathological Grade of Gliomas - a Prospective Study." *Asian J Neurosurg* 14, no. 1 (2019): 47-51.
236. Aydin, Sonay, Erdem Fatihoğlu, Pınar Nercis Koşar, and Elif Ergün. "Perfusion and Permeability Mri in Glioma Grading." *Egyptian Journal of Radiology and Nuclear Medicine* 51, no. 1 (2020): 2.
237. Álvarez-Torres, María del Mar, Elies Fuster-García, Javier Juan-Albarracín, Gaspar Reynés, Fernando Aparici-Robles, Jaime Ferrer-Lozano, and Juan Miguel García-Gómez. "Local Detection of Microvessels in Idh-Wildtype Glioblastoma Using Relative Cerebral Blood Volume: An Imaging Marker Useful for Astrocytoma Grade 4 Classification." *BMC Cancer* 22, no. 1 (2022): 40.
238. Feraco, P., A. Bacci, P. Ferrazza, L. van den Hauwe, R. Pertile, S. Girlando, M. Barbareschi, C. Gagliardo, A. G. Morganti, and B. Petralia. "Magnetic Resonance Imaging Derived Biomarkers of Idh Mutation Status and Overall Survival in Grade Iii Astrocytomas." *Diagnostics (Basel)* 10, no. 4 (2020).
239. Tan, W. L., W. Y. Huang, B. Yin, J. Xiong, J. S. Wu, and D. Y. Geng. "Can Diffusion Tensor Imaging Noninvasively Detect Idh1 Gene Mutations in Astroglomas? A Retrospective Study of 112 Cases." *AJNR Am J Neuroradiol* 35, no. 5 (2014): 920-7.
240. Kurokawa, Ryo, Akira Baba, Mariko Kurokawa, Aristides Capizzano, Yoshiaki Ota, John Kim, Ashok Srinivasan, and Toshio Moritani. "Perfusion and Diffusion-Weighted Imaging Parameters: Comparison between Pre- and Postbiopsy Mri for High-Grade Glioma." *Medicine* 101, no. 35 (2022).
241. Gühr, G., D. Horvath-Rizea, P. Kohlhof-Meinecke, O. Ganslandt, H. Henkes, W. Härtig, A. Donitza, M. Skalej, and S. Schob. "Diffusion Weighted Imaging in Gliomas: A Histogram-Based Approach for Tumor Characterization." *Cancers (Basel)* 14, no. 14 (2022).
242. Cho, Nicholas S, Akifumi Hagiwara, Blaine S C Eldred, Catalina Raymond, Chencai Wang, Francesco Sanvito, Albert Lai, Phioanh Nghiemphu, Noriko Salamon, Lori Steelman, Islam Hassan, Timothy F Cloughesy, and Benjamin M Ellingson. "Early Volumetric, Perfusion, and Diffusion Mri Changes after Mutant Isocitrate Dehydrogenase (Idh) Inhibitor Treatment in Idh1-Mutant Gliomas." *Neuro-Oncology Advances* 4, no. 1 (2022).
243. Stadlbauer, Andreas, Katarina Nikolic, Stefan Oberndorfer, Franz Marhold, Thomas M. Kinfe, Anke Meyer-Bäse, Diana Alina Bistran, Oliver Schnell, and Arnd Doerfler. "Machine Learning-Based Prediction of Glioma Idh Gene Mutation Status Using Physio-Metabolic Mri of Oxygen Metabolism and Neovascularization (a Bicenter Study)." *Cancers* 16, no. 6 (2024): 1102.
244. Yuan, Jialin, Loizos Siakallis, Hongwei Bran Li, Sebastian Brandner, Jianguo Zhang, Chenming Li, Laura Mancini, and Sotirios Bisdas. "Structural- and Dti- Mri Enable Automated Prediction of Idh Mutation Status in Cns Who Grade 2-4 Glioma Patients: A Deep Radiomics Approach." *BMC Medical Imaging* 24, no. 1 (2024): 104.
245. Liu, Z., X. Xu, W. Zhang, L. Zhang, M. Wen, J. Gao, J. Yang, Y. Kan, X. Yang, Z. Wen, S. Chen, and X. Cao. "A Fusion Model Integrating Magnetic Resonance Imaging Radiomics and Deep Learning Features for Predicting Alpha-Thalassemia X-Linked Intellectual Disability Mutation Status in Isocitrate Dehydrogenase-Mutant High-Grade Astrocytoma: A Multicenter Study." *Quant Imaging Med Surg* 14, no. 1 (2024): 251-63.
246. Tang, W. T., C. Q. Su, J. Lin, Z. W. Xia, S. S. Lu, and X. N. Hong. "T2-Flair Mismatch Sign and Machine Learning-Based Multiparametric Mri Radiomics in Predicting Idh Mutant 1p/19q Non-Co-Deleted Diffuse Lower-Grade Gliomas." *Clinical Radiology* 79, no. 5 (2024): e750-e58.
247. Santinha, João, Vasileios Katsaros, George Stranjalis, Evangelia Liouta, Christos Boskos, Celso Matos, Catarina Viegas, and Nickolas Papanikolaou. "Development of End-to-End Ai-Based Mri Image Analysis System for Predicting Idh Mutation Status of Patients with Gliomas: Multicentric Validation." *Journal of Imaging Informatics in Medicine* 37, no. 1 (2024): 31-44.
248. Pasquini, Luca, Antonio Napolitano, Emanuela Tagliente, Francesco Dellepiane, Martina Lucignani, Antonello Vidiri, Giulio Ranazzi, Antonella Stoppacciaro, Giulia Moltoni, Matteo Nicolai, Andrea Romano, Alberto Di Napoli, and Alessandro Bozzao. "Deep Learning Can Differentiate Idh-Mutant from Idh-Wild Gbm." *Journal of Personalized Medicine* 11, no. 4 (2021): 290.

249. Carosi, Francesca, Elisabetta Broseghini, Laura Fabbri, Giacomo Corradi, Riccardo Gili, Valentina Forte, Roberta Roncarati, Daria Maria Filippini, and Manuela Ferracin. "Targeting Isocitrate Dehydrogenase (Idh) in Solid Tumors: Current Evidence and Future Perspectives." *Cancers* 16, no. 15 (2024): 2752.
250. Iwahashi, Hirofumi, Hiroaki Nagashima, Kazuhiro Tanaka, Takiko Uno, Mitsuru Hashiguchi, Masahiro Maeyama, Yuichiro Somiya, Masato Komatsu, Takanori Hirose, Tomoo Itoh, Ryohei Sasaki, and Takashi Sasayama. "2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Adult Brainstem Glioma." *Journal of Neurosurgery* 139, no. 2 (2023): 355-62.
251. Suh, C. H., H. S. Kim, S. C. Jung, C. G. Choi, and S. J. Kim. "2-Hydroxyglutarate Mr Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-Analysis Using Individual Patient Data." *Neuro Oncol* 20, no. 12 (2018): 1573-83.
252. Bhandari, A., C. Sharma, M. Ibrahim, M. Riggs, R. Jones, and A. Lasocki. "The Role of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy for the Determination of Isocitrate Dehydrogenase Status in Lower Grade Gliomas Versus Glioblastoma: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy." *Neuroradiology* 63, no. 11 (2021): 1823-30.
253. Branzoli, F., A. L. Di Stefano, L. Capelle, C. Ottolenghi, R. Valabrègue, D. K. Deelchand, F. Bielle, C. Villa, B. Baussart, S. Lehericy, M. Sanson, and M. Marjanska. "Highly Specific Determination of Idh Status Using Edited in Vivo Magnetic Resonance Spectroscopy." *Neuro Oncol* 20, no. 7 (2018): 907-16.
254. Zhou, M., Y. Zhou, H. Liao, B. C. Rowland, X. Kong, N. D. Arvold, D. A. Reardon, P. Y. Wen, A. P. Lin, and R. Y. Huang. "Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly Diagnosed Brain Mass and Suspected Recurrent Gliomas." *Neuro Oncol* 20, no. 9 (2018): 1262-71.
255. Tietze, A., C. Choi, B. Mickey, E. A. Maher, B. Parm Ulhøi, R. Sangill, Y. Lassen-Ramshad, S. Lukacova, L. Østergaard, and G. von Oettingen. "Noninvasive Assessment of Isocitrate Dehydrogenase Mutation Status in Cerebral Gliomas by Magnetic Resonance Spectroscopy in a Clinical Setting." *J Neurosurg* 128, no. 2 (2018): 391-98.
256. Andronesi, Ovidiu C., Otto Rapalino, Elizabeth Gerstner, Andrew Chi, Tracy T. Batchelor, Dan P. Cahill, A. Gregory Sorensen, and Bruce R. Rosen. "Detection of Oncogenic Idh1 Mutations Using Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate." *The Journal of Clinical Investigation* 123, no. 9 (2013): 3659-63.
257. Andronesi, O. C., I. C. Arrillaga-Romany, K. I. Ly, W. Bogner, E. M. Ratai, K. Reitz, A. J. Iafrate, J. Dietrich, E. R. Gerstner, A. S. Chi, B. R. Rosen, P. Y. Wen, D. P. Cahill, and T. T. Batchelor. "Pharmacodynamics of Mutant-Idh1 Inhibitors in Glioma Patients Probed by in Vivo 3d MRS Imaging of 2-Hydroxyglutarate." *Nat Commun* 9, no. 1 (2018): 1474.
258. Liang, Jianfeng, Xiaomin Lv, Changyu Lu, Xun Ye, Xiaolin Chen, Jia Fu, Chenghua Luo, and Yuanli Zhao. "Prognostic Factors of Patients with Gliomas – an Analysis on 335 Patients with Glioblastoma and Other Forms of Gliomas." *BMC Cancer* 20, no. 1 (2020): 35.
259. Louis, David N, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger, Riccardo Soffietti, Andreas von Deimling, and David W Ellison. "The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary." *Neuro-Oncology* 23, no. 8 (2021): 1231-51.
260. Ostrom, Q. T., N. Patil, G. Cioffi, K. Waite, C. Kruchko, and J. S. Barnholtz-Sloan. "Cbtrus Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017." *Neuro Oncol* 22, no. 12 Suppl 2 (2020): iv1-iv96.
261. Shirahata, M., T. Ono, D. Stichel, D. Schrimpf, D. E. Reuss, F. Sahm, C. Koelsche, A. Wefers, A. Reinhardt, K. Huang, P. Sievers, H. Shimizu, H. Nanjo, Y. Kobayashi, Y. Miyake, T. Suzuki, J. I. Adachi, K. Mishima, A. Sasaki, ..., and A. von Deimling. "Novel, Improved Grading System(S) for Idh-Mutant Astrocytic Gliomas." *Acta Neuropathol* 136, no. 1 (2018): 153-66.
262. Parsons, D. W., S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz, Jr., ..., and K. W. Kinzler. "An Integrated Genomic Analysis of Human Glioblastoma Multiforme." *Science* 321, no. 5897 (2008): 1807-12.
263. Yan, H., D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, and D. D. Bigner. "Idh1 and Idh2 Mutations in Gliomas." *N Engl J Med* 360, no. 8 (2009): 765-73.
264. Lopez-Gines, C., M. Cerda-Nicolas, R. Gil-Benso, A. Pellin, J. A. Lopez-Guerrero, R. Callaghan, R. Benito, P. Roldan, J. Piquer, J. Llacer, and J. Barbera. "Association of Chromosome 7, Chromosome 10 and Egfr Gene Amplification in Glioblastoma Multiforme." *Clin Neuropathol* 24, no. 5 (2005): 209-18.
265. Eckel-Passow, Jeanette E., Daniel H. Lachance, Annette M. Molinaro, Kyle M. Walsh, Paul A. Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L. Kosel, Ivan V. Smirnov, Gobinda Sarkar, Alissa A. Caron, Thomas M. Kollmeyer, Corinne E. Praska, Anisha R. Chada, Chandralekha Halder, Helen M. Hansen, Lucie S. McCoy, Paige M. Bracci, ..., and Robert B. Jenkins. "Glioma Groups Based on 1p/19q,

- <I>Idh</I>, and <I>Tert</I> Promoter Mutations in Tumors." *New England Journal of Medicine* 372, no. 26 (2015): 2499-508.
266. Killela, P. J., Z. J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, L. A. Diaz, Jr., A. H. Friedman, H. Friedman, G. L. Gallia, B. C. Giovanella, A. P. Grollman, T. C. He, Y. He, R. H. Hruban, G. I. Jallo, N. Mandahl, A. K. Meeker, F. Mertens, G. J. Netto, ..., and H. Yan. "Tert Promoter Mutations Occur Frequently in Gliomas and a Subset of Tumors Derived from Cells with Low Rates of Self-Renewal." *Proc Natl Acad Sci U S A* 110, no. 15 (2013): 6021-6.
 267. Spiegl-Kreinecker, Sabine, Daniela Lötsch, Bahil Ghanim, Christine Pirker, Thomas Mohr, Magdalena Laaber, Serge Weis, Alfred Olschowski, Gerald Webersinke, Josef Pichler, and Walter Berger. "Prognostic Quality of Activating Tert Promoter Mutations in Glioblastoma: Interaction with the Rs2853669 Polymorphism and Patient Age at Diagnosis." *Neuro-Oncology* 17, no. 9 (2015): 1231-40.
 268. Ebrahimi, A., M. Skardelly, I. Bonzheim, I. Ott, H. Mühleisen, F. Eckert, G. Tabatabai, and J. Schittenhelm. "Atrx Immunostaining Predicts Idh and H3f3a Status in Gliomas." *Acta Neuropathol Commun* 4, no. 1 (2016): 60.
 269. Weller, Michael, Patrick Y. Wen, Susan M. Chang, Linda Dirven, Michael Lim, Michelle Monje, and Guido Reifenberger. "Glioma." *Nature Reviews Disease Primers* 10, no. 1 (2024): 33.
 270. Pusch, Stefan, Leonille Schweizer, Ann-Christin Beck, Johanna-Marie Lehmler, Susanne Weissert, Jörg Balss, Aubry K. Miller, and Andreas von Deimling. "D-2-Hydroxyglutarate Producing Neo-Enzymatic Activity Inversely Correlates with Frequency of the Type of Isocitrate Dehydrogenase 1 Mutations Found in Glioma." *Acta Neuropathologica Communications* 2, no. 1 (2014): 19.
 271. Natsumeda, M., H. Igarashi, T. Nomura, R. Ogura, Y. Tsukamoto, T. Kobayashi, H. Aoki, K. Okamoto, A. Kakita, H. Takahashi, T. Nakada, and Y. Fujii. "Accumulation of 2-Hydroxyglutarate in Gliomas Correlates with Survival: A Study by 3.0-Tesla Magnetic Resonance Spectroscopy." *Acta Neuropathol Commun* 2 (2014): 158.
 272. Brennan, C. W., R. G. Verhaak, A. McKenna, B. Campos, H. Nounshmehr, S. R. Salama, S. Zheng, D. Chakravarty, J. Z. Sanborn, S. H. Berman, R. Beroukhi, B. Bernard, C. J. Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna, S. A. Shukla, ..., and L. Chin. "The Somatic Genomic Landscape of Glioblastoma." *Cell* 155, no. 2 (2013): 462-77.
 273. Ceccarelli, M., F. P. Barthel, T. M. Malta, T. S. Sabedot, S. R. Salama, B. A. Murray, O. Morozova, Y. Newton, A. Radenbaugh, S. M. Pagnotta, S. Anjum, J. Wang, G. Manyam, P. Zoppoli, S. Ling, A. A. Rao, M. Grifford, A. D. Cherniack, H. Zhang, ..., and R. G. Verhaak. "Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma." *Cell* 164, no. 3 (2016): 550-63.
 274. Aoki, Kosuke, Hideo Nakamura, Hiromichi Suzuki, Keitaro Matsuo, Keisuke Kataoka, Teppei Shimamura, Kazuya Motomura, Fumiharu Ohka, Satoshi Shiina, Takashi Yamamoto, Yasunobu Nagata, Tetsuichi Yoshizato, Masahiro Mizoguchi, Tatsuya Abe, Yasutomo Momii, Yoshihiro Muragaki, Reiko Watanabe, Ichiro Ito, Masashi Sanada, ..., and Atsushi Natsume. "Prognostic Relevance of Genetic Alterations in Diffuse Lower-Grade Gliomas." *Neuro-Oncology* 20, no. 1 (2017): 66-77.
 275. Yang, R. R., Z. F. Shi, Z. Y. Zhang, A. K. Chan, A. Aibaidula, W. W. Wang, J. S. H. Kwan, W. S. Poon, H. Chen, W. C. Li, N. Y. Chung, G. Punchhi, W. C. Chu, I. S. Chan, X. Z. Liu, Y. Mao, K. K. Li, and H. K. Ng. "Idh Mutant Lower Grade (Who Grades Ii/Iii) Astrocytomas Can Be Stratified for Risk by Cdkn2a, Cdk4 and Pdgfra Copy Number Alterations." *Brain Pathol* 30, no. 3 (2020): 541-53.
 276. Johnson, B. E., T. Mazor, C. Hong, M. Barnes, K. Aihara, C. Y. McLean, S. D. Fouse, S. Yamamoto, H. Ueda, K. Tatsuno, S. Asthana, L. E. Jalbert, S. J. Nelson, A. W. Bollen, W. C. Gustafson, E. Charron, W. A. Weiss, I. V. Smirnov, J. S. Song, ..., and J. F. Costello. "Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma." *Science* 343, no. 6167 (2014): 189-93.
 277. Suzuki, H., K. Aoki, K. Chiba, Y. Sato, Y. Shiozawa, Y. Shiraiishi, T. Shimamura, A. Niida, K. Motomura, F. Ohka, T. Yamamoto, K. Tanahashi, M. Ranjit, T. Wakabayashi, T. Yoshizato, K. Kataoka, K. Yoshida, Y. Nagata, A. Sato-Otsubo, ..., and S. Ogawa. "Mutational Landscape and Clonal Architecture in Grade Ii and Iii Gliomas." *Nat Genet* 47, no. 5 (2015): 458-68.
 278. Favero, F., N. McGranahan, M. Salm, N. J. Birkbak, J. Z. Sanborn, S. C. Benz, J. Becq, J. F. Peden, Z. Kingsbury, R. J. Grocock, S. Humphray, D. Bentley, B. Spencer-Dene, A. Gutteridge, M. Brada, S. Roger, P. Y. Dietrich, T. Forshew, M. Gerlinger, ..., and C. Swanton. "Glioblastoma Adaptation Traced through Decline of an Idh1 Clonal Driver and Macro-Evolution of a Double-Minute Chromosome." *Ann Oncol* 26, no. 5 (2015): 880-87.
 279. Lopez, G. Y., N. A. Oberheim Bush, J. J. Phillips, J. P. Bouffard, Y. A. Moshel, K. Jaecle, B. K. Kleinschmidt-DeMasters, M. K. Rosenblum, A. Perry, and D. A. Solomon. "Diffuse Midline Gliomas with Subclonal H3f3a K27m Mutation and Mosaic H3.3 K27m Mutant Protein Expression." *Acta Neuropathol* 134, no. 6 (2017): 961-63.
 280. Luo, S., S. Zhu, J. Liao, Y. Zhang, X. Hou, T. Luo, E. Zhao, J. Xu, L. Pang, X. Liang, Y. Xiao, and X. Li. "Idh Clonal Heterogeneity Segregates a Subgroup of Non-1p/19q Codeleted Gliomas with Unfavourable Clinical Outcome." *Neuropathol Appl Neurobiol* 47, no. 3 (2021): 394-405.

281. Nicholson, J. G., and H. A. Fine. "Diffuse Glioma Heterogeneity and Its Therapeutic Implications." *Cancer Discov* 11, no. 3 (2021): 575-90.
282. Morgan, K. M., S. Danish, and Z. Xiong. "Diffuse Astrocytoma with Mosaic Idh1-R132H-Mutant Immuno-Phenotype and Low Subclonal Allele Frequency." *Intractable Rare Dis Res* 11, no. 1 (2022): 43-45.
283. Bai, M., X. Wang, H. Zhang, J. Wang, G. Lyaysan, S. Xu, K. Tian, T. Wang, J. Li, N. Wang, X. Lu, X. Zhang, and L. Wang. "Dissecting and Analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma." *Biomed Res Int* 2022 (2022): 4919111.
284. Voisin, M. R., C. Gui, V. Patil, A. F. Gao, and G. Zadeh. "Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation over Time." *Can J Neurol Sci* (2023): 1-7.
285. Senft, C., M. Behrens, I. Lortz, K. Wenger, K. Filipowski, V. Seifert, and M. T. Forster. "The Ability to Return to Work: A Patient-Centered Outcome Parameter Following Glioma Surgery." *J Neurooncol* 149, no. 3 (2020): 403-11.
286. van Loon, E. M. P., W. Ernens, M. H. Heijnenbroek-Kal, H. L. D. Horemans, G. M. Ribbers, and M. J. van den Bent. "Long-Term Employment Status and the Association with Fatigue in Patients with Grade II Glioma." *J Rehabil Med* 53, no. 5 (2021): jrm00198.
287. Birendra, K. C., and C. D. DiNardo. "Evidence for Clinical Differentiation and Differentiation Syndrome in Patients with Acute Myeloid Leukemia and Idh1 Mutations Treated with the Targeted Mutant Idh1 Inhibitor, Ag-120." *Clin Lymphoma Myeloma Leuk* 16, no. 8 (2016): 460-5.
288. Fujii, T., M. R. Khawaja, C. D. DiNardo, J. T. Atkins, and F. Janku. "Targeting Isocitrate Dehydrogenase (Idh) in Cancer." *Discov Med* 21, no. 117 (2016): 373-80.
289. Mellingerhoff, I. K., M. J. van den Bent, D. T. Blumenthal, M. Touat, K. B. Peters, J. Clarke, J. Mendez, S. Yust-Katz, L. Welsh, W. P. Mason, F. Ducray, Y. Umemura, B. Nabors, M. Holdhoff, A. F. Hottinger, Y. Arakawa, J. M. Sepulveda, W. Wick, R. Soffietti, ..., and Indigo Trial Investigators. "Vorasidenib in Idh1- or Idh2-Mutant Low-Grade Glioma." *N Engl J Med* 389, no. 7 (2023): 589-601.
290. Wen, Fei, Gang Gui, Xiaoyu Wang, Anqi Qin, Tianfang Ma, Hui Chen, Chunzheng Li, and Xiaoming Zha. "Discovery of Novel Dual Inhibitors Targeting Mutant Idh1 and Npm1 for the Treatment of Glioma with Idh1 Mutation." *Journal of Medicinal Chemistry* 67, no. 11 (2024): 8667-92.
291. Moore, D. "Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma." *P t* 41, no. 5 (2016): 296-300.
292. Pan, Darren, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier, and Joshua Richter. "Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients." *Seminars in Oncology* 50, no. 1 (2023): 40-48.
293. Gunn, Kathryn, Matti Myllykoski, John Z. Cao, Manna Ahmed, Bofu Huang, Betty Rouaisnel, Bill H. Diplas, Michael M. Levitt, Ryan Looper, John G. Doench, Keith L. Ligon, Harley I. Komblum, Samuel K. McBrayer, Hai Yan, Cihangir Duy, Lucy A. Godley, Peppi Koivunen, and Julie-Aurore Losman. "(R)-2-Hydroxyglutarate Inhibits Kdm5 Histone Lysine Demethylases to Drive Transformation in Idh-Mutant Cancers." *Cancer Discovery* 13, no. 6 (2023): 1478-97.
294. Nie, Zhe, Lihong Shi, Chon Lai, Shawn M. O'Connell, Jiangchun Xu, Ryan K. Stansfield, David J. Hosfield, James M. Veal, and Jeffrey A. Stafford. "Structure-Based Design and Discovery of Potent and Selective Kdm5 Inhibitors." *Bioorganic & Medicinal Chemistry Letters* 28, no. 9 (2018): 1490-94.
295. Rautajoki, K. J., S. Jaatinen, A. Hartewig, A. M. Tiihonen, M. Annala, I. Salonen, M. Valkonen, V. Simola, E. M. Vuorinen, A. Kivinen, M. J. Rauhala, R. Nurminen, K. K. Maass, S. L. Lahtela, A. Jukkola, O. Yli-Harja, P. Helén, K. W. Pajtler, P. Ruusuvoori, ..., and M. Nykter. "Genomic Characterization of Idh-Mutant Astrocytoma Progression to Grade 4 in the Treatment Setting." *Acta Neuropathol Commun* 11, no. 1 (2023): 176.
296. Weller, M., J. Felsberg, B. Hentschel, D. Gramatzki, N. Kubon, M. Wolter, M. Reusche, P. Roth, D. Krex, U. Herrlinger, M. Westphal, J. C. Tonn, L. Regli, C. A. Maurage, A. von Deimling, T. Pietsch, E. Le Rhun, and G. Reifenberger. "Improved Prognostic Stratification of Patients with Isocitrate Dehydrogenase-Mutant Astrocytoma." *Acta Neuropathol* 147, no. 1 (2024): 11.
297. Sharma, N., A. N. Mallela, D. D. Shi, L. W. Tang, H. Abou-Al-Shaar, Z. C. Gersey, X. Zhang, S. K. McBrayer, and K. G. Abdullah. "Isocitrate Dehydrogenase Mutations in Gliomas: A Review of Current Understanding and Trials." *Neurooncol Adv* 5, no. 1 (2023): vdad053.
298. Kayabolen, A., E. Yilmaz, and T. Bagci-Onder. "Idh Mutations in Glioma: Double-Edged Sword in Clinical Applications?" *Biomedicine* 9, no. 7 (2021).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.